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ABSTRACT
ONCOLOGY NURSES’ ATTITUDES TOWARD CANCER CLINICAL TRIALS
AND THEIR PERCEPTIONS OF PATIENTS’ UNDERSTANDING
by
Paul G. D’Amico
Duquesne University

Clinical trials in oncology that evaluate new cancer treatments are essential.
However, in the United States only 2%-4% of eligible adult cancer patients participate in
the National Cancer Institute’s clinical trials annually. Oncology nurses have a major role
in the care of patients contemplating enrollment into cancer clinical trials, yet little is
known about their attitudes, beliefs, and perceptions.
The Modified Nursing Attitude Survey and a demographic form were used to
collect data. This study discovered significant predictors to attitudes and perceptions;
however, all R² (coefficient of determination) values were very low, which indicates that
some other unknown variables could be better predictors than those used in this study. On
average, oncology nurses reported positive attitudes towards cancer clinical trials.
However, statistically significant differences were found between nurses grouped by
primary work setting and primary position. Additionally, as a whole, these nurses
perceived that patients have enough information to make decisions regarding clinical trial
participation, but they somewhat disagreed that: clinical research should be conducted
only in cancer centers, oncologists and nurses put too much pressure on patients to
participate, and patients are often unaware that their treatment is part of a research
protocol. Significant differences in these perceptions were found between: primary work
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setting, number of years in cancer nursing, and whether or not the nurse works with these
patients. Consistent with prior research, oncology nurses perceive that experimental
cancer treatments should have a large benefit before being offered. Moreover, there were
statistically significant differences in this perceived benefit among the nurses grouped by
number of years in cancer nursing, primary work setting, and education level. More
research is needed to explore the reasons for these differences in attitudes and
perceptions.
This study explored nurses’ attitudes and perceptions regarding cancer clinical
trials. Since their attitudes may ultimately dictate their behaviors towards clinical trials,
this study has far reaching implications for nursing education, nursing practice, and the
conduct of clinical trials. By investigating oncology nurses’ attitudes and perceptions
toward cancel clinical trials this study begins to assess the behavior of oncology nurses
towards cancer patients.

Dissertation Advisor: Gladys L. Husted, PhD, RN
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CHAPTER I: INTRODUCTION
A. Background
History of Human Subject Research
Experiments performed by the Nazis on concentration-camp inmates are some of
the most well-known atrocities to date. Out of this horror came the first formalized set of
ethical rules for the conduct of human experimentation. In the aftermath of the war, the
Nuremberg Tribunal prosecuted the perpetrators and, in 1946, developed a set of ethical
principles that have come to be known as the Nuremberg Code. The Code sets out 10
ethical principles for the conduct of clinical trials. The first is the most important: “The
voluntary consent of the human subject is absolutely essential.” Moreover, this consent
must be obtained “without the intervention of any element of force, fraud, deceit, duress,
over-reaching, or other ulterior form of constraint or coercion” (Nuremberg Military
Tribunal, 1949, p. 181).
In June 1966, Henry K. Beecher, an anesthesiologist at Harvard Medical School,
published an article entitled “Ethics and Clinical Research” in the New England Journal
of Medicine (Beecher, 1966). In his article, he listed more than 22 clinical trials that
appeared to be highly unethical, in which investigators risked their patients’ lives without
fully informing them of the dangers and without obtaining their permission. The “Ethics
and Clinical Research” article had a significant role in the development of requirements
for informed consent of research subjects.
In 1970, the Tuskegee experiment was revealed. Starting in 1930 and continuing
for four decades, investigators began examining, but not treating, a group of 400 AfricanAmerican men who had syphilis. The investigators were interested in watching the
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natural course of the disease. In 1930, the existing treatments for syphilis were complex
and not very effective, so the investigators felt they were justified in not treating the men.
Penicillin as a highly effective cure for syphilis became available widely in 1945.
However, many of the men were left untreated until the situation was uncovered in 1970
(Finn, 1999).
The publicity from the Tuskegee Syphilis Study prompted the National Research
Act of 1974 that created the National Commission for the Protection of Human Subjects
of Biomedical and Behavioral Research (National Cancer Institute, 1979). One charge to
the Commission was to identify the basic ethical principles that should underlie the
conduct of biomedical and behavioral research involving human subjects and to develop
guidelines to assure that such research is conducted in accordance with those principles
(Public Law 93-348, 1974).
In carrying out the above charge, the Commission was directed to consider the
following: the boundaries between biomedical and behavioral research and the accepted
and routine practice of medicine; the role of assessment of risk-benefit criteria in the
determination of the appropriateness of research involving human subjects; appropriate
guidelines for the selection of human subjects for participation in such research; and the
nature and definition of informed consent in various research settings (National Cancer
Institute, 1979).
The Belmont Report summarizes the basic ethical principles identified by the
Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research (National Cancer Institute, 1979). It is the outgrowth of an intensive four day
period of discussions held in February 1976 at the Smithsonian Institution‘s Belmont
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Conference Center and supplemented by monthly deliberations of the Commission that
were held over a period of nearly 4 years. It is a statement of basic ethical principles and
guidelines that should assist in resolving the ethical problems that surround the conduct
of research with human subjects (Office of Behavioral and Social Sciences Research,
2003).
The three basic ethical principles for the conduct of clinical trials discussed in the
Belmont Report are respect for persons, beneficence, and justice (National Institutes of
Health, 1979). In applying those principles, the authors recommended that consideration
be given to three requirements:
1. Informed consent: In order to provide fully informed consent, a potential
research subject must first be given full information about the research project. Second,
that information must be presented in a comprehensible way, taking into account the
patient‘s intellectual capacities. Third, the consent must be truly voluntary, and free from
coercion and undue influence.
2. Assessment of risks and benefits: The dangers of any clinical trial must not
exceed its potential benefits.
3. Selection of subjects: There must be fair procedures for the selection of
research subjects (National Institutes of Health, 1979).
Therapeutic Clinical Trials
A clinical trial is clinical research “designed to answer a question that has
therapeutic implications for patients” (Hubbard, 1985, p. 67). The most familiar clinical
trials in oncology are the ones that evaluate new methods of screening, prevention,
diagnosis, or treatment of cancer (National Institutes of Health, 2006). Clinical trials are
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generally divided into four main phases. Each has a separate and particular goal, and each
successive phase builds upon the previous one (Grady, 1991).
Phase I studies. Phase I studies are unblinded and uncontrolled. They are
designed to evaluate the maximum tolerated dose (MTD) and the safety of a new drug or
combination of drugs and a given administration schedule in human subjects (Johansen,
Mayer, & Hoover, 1991; Yoder, O’Rourke, Etnyre, Spears, & Brown, 1997). MTD and
treatment schedule are the endpoints of a Phase I trial, thus antitumor or disease response
may not be noted (Jenkins & Hubbard, 1991; Johansen et al., 1991).
Patients eligible for these trials are generally those with less than three months to
live and have no alternative available treatment options. Some patients will receive a
treatment which has no benefit to them, since these trials offer no guarantee of efficacy.
However, there is an important characteristic that can be of value to patients. There is the
possibility that the new treatment, which looks promising in the laboratory, may continue
to invoke its same promising characteristics in humans (Sadler, Lantz, Fullerton, & Dault,
1999). These trials offer patients a ray of hope even though the Phase I trial is concerned
only with establishing the MTD. Qualitative studies conducted with patients enrolled into
Phase I clinical trials discovered hope as a recurrent theme (Cox, 1999; Cox & Avis,
1996; Moore, 2001; Schutta & Burnett, 2000; Yoder et al., 1997).
Phase II studies. At the completion of a Phase I study, the MTD is established. It
is at this dose level that Phase II studies are designed to determine the activity and
efficacy of a drug or treatment against a specific disease. The timing and frequency of
objective tumor measurements before, during, and after treatment must be specified and
strictly followed (Sadler et al., 1999).
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If the findings from the Phase II study show promise that the intervention is
equivalent to, or better than, currently available therapies, then the intervention is moved
into Phase III evaluation.
Phase III studies. Once a medication demonstrates efficacy in Phase II testing,
Phase II studies are conducted. Phase III studies are large randomized, controlled studies
(they may be blinded, but not always) designed to test the investigational agent(s) against
the accepted standards of care. Survival, quality-of-life, and cost-effectiveness are
assessed in a Phase III trial (Jenkins & Hubbard, 1991).
Patients who are eligible for a Phase III clinical trial typically are at an earlier
stage of diagnosis than in previous phases, and conform to narrowly defined inclusion
and exclusion criteria for participation (Sadler et al., 1999).
At the completion of a Phase III trial there will be a more thorough understanding
of the new therapies’ benefits and potential adverse reactions. Upon successful
completion of a Phase III trail, the sponsor of the trial (pharmaceutical company, or
government agency, etc.) can request Food and Drug Administration (FDA) approval to
market the therapy for the specified condition evaluated in the trial (Sadler et al., 1999).
Phase IV studies. After a treatment receives FDA approval, Phase IV studies,
commonly known as post-marketing studies, are conducted. They “assess the rate of
serious side effects and evaluate additional therapeutic uses of the therapy” (Grady,
Cummings, & Hulley, 2001 p. 170). These studies could include, but would not be
limited to, examining different doses or schedules of administration than were previously
used in Phase II studies, use of the drug in other patient populations or other stages of the
disease, or use of the drug over longer time periods to assess long-term safety.
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B. The Problem
The majority of advances in cancer treatment come in small steps achieved
through clinical trials in which new drugs and treatments are carefully studied on human
subjects. Thus, the ethics of research, especially regarding the rights of patients, becomes
vital to this endeavor. Clinical trials are an important step in helping translate potentially
beneficial basic research findings into clinical practice (Grunfeld, Zitelsberger, Coristine,
& Aspelund, 2002). It is vital to recruit as many eligible patients as possible for studies,
and to do so in an ethical manner. Clinical trials in oncology that evaluate new treatments
are essential. However, in the United States (US) only two to four percent (N = 28,00056,000) of all newly diagnosed adult cancer patients annually participate in National
Cancer Institute (NCI) clinical trials (Lara, et al., 2001). This is despite estimates that
12%–44% (N = 168,000-616,000) of adults with cancer are eligible for entry (Morrow,
Hickok, & Burish, 1994). According to the NCI, this is in sharp contrast to the enrollment
of pediatric cancer patients into clinical trials, which approaches 50-80% (N = 6,200 –
9920) (Ries, et al., 1999; Sateren, et al., 2002). This strong enrollment of children with
cancer is due in part to the fact that most children are treated at academic medical centers
with experts’ in pediatric oncology (Sateren, et al., 2002).
A total of 1,399,790 new cancer cases and 564,830 deaths from cancer are
expected in the U.S. in 2006 (Jemal, et al., 2006). This is a greater concern when ageadjusted death rates are considered. Cancer in the U.S is the leading cause of death
among men and women under age 85 (Jemal, et al., 2006). A total of 476,844 people
under age 85 died from cancer in the U.S. in 2003, compared with 436,258 deaths from
heart disease (Jemal, et al., 2006). Therefore, recruitment and retention of adult
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participants into oncology clinical trials is critical to the outcome and success of clinical
trial research. However, concerns exist about the ability of clinical investigators to
provide sufficient information to patients regarding research trial participation so that
patients can recognize the distinction between research and therapy (Bok, 1995). The
shortage of clinical trial participants often results in early trial closure, increased cost,
compromised generalizability of the findings, and delays in the development and
adoption of new treatments (Barrett, 2002).
Today, the vast majority of clinical trials relate to treatment decisions. When
patients consider treatments, they base their decisions upon many factors, including
available information (Llewellyn-Thomas, McGreal, & Theil, 1995). Nealon, Blumberg,
and Brown (1985) reported on an unpublished NCI pilot study investigating the
educational needs of cancer patients considering clinical trials and to develop ways to
meet these needs. At the time there were few educational materials that explained clinical
trials to patients and families. The NCI conducted an assessment with the following
participants (N = 53): 16 cancer patients currently in trials and 4 family members, 4 NCI
cancer control staff, 18 physicians (7 NCI staff and 11 community physicians), 8
oncology nurses, 2 oncology social workers, and 1 health educator (Nealon, Blumberg, &
Brown, 1985). Patients reported that although they do not know what to ask, when they
do ask questions, they are more likely to ask a nurse than a doctor. Therefore, patients
considering investigational therapy may receive much of their information about options
from nurses. From the experience of this investigator, this remains true today. It is
ethically essential for healthcare professionals to provide patients with the information
required to promote informed decisions (Beauchamp & Childress, 2001).
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Oncology nurses participate in all aspects of clinical trials as direct care givers,
research nurses, research partners, and primary investigators. They also administer
experimental agents to patients, manage side effects, and obtain informed consent
(Ehrenberger & Lillington, 2004; Joshi & Ehrenberger, 2001; Rosse & Krebs, 1999).
Oncology nurses have a major role in cancer clinical trials, such as direct caregivers,
patient advocates, educators, counselors, as well as facilitators of clinical trials. Yet, not
much is known about their attitudes, beliefs, and perceptions.
C. Purpose
The purpose of this study was to examine oncology nurses’ attitudes toward
cancer clinical trials and to identify nurses’ perceptions of patients’ understanding of the
clinical trial process and desire for information and, reasons for patient participation in
clinical research. This study investigated factors which may influence oncology nurses’
attitudes and perceptions. They included the nurses’ age, educational preparation, length
of time in oncology nursing, whether of not the nurse actually cares for patients
contemplating enrollment or currently enrolled in a clinical trial, primary position, and
work setting.
D. Research Questions
The following research questions guided this inquiry:
1. What are oncology nurses’ attitudes toward the benefits of cancer clinical
trials?
2. What are nurses attitudes about how effective a research drug or experimental
therapy should be shown to be before it is offered to patients?
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3. What are the nurses’ perceptions regarding patients’ understanding and
knowledge of the treatment regimen?
4. What factors do nurses perceive influence a patient’s decision to participate in a
cancer clinical trial?
5. What are nurses’ perceptions of patients’ decision-making processes and the
desire for information regarding clinical trial participation?
6. What are the perceptions of nurses regarding where clinical research should be
conducted and the role of oncologists and nurses in clinical trials?
7. Do the demographic variables of age, education level, number of years in
oncology, whether or not the nurse actually works with patients contemplating enrollment
or currently enrolled in a clinical trial, primary work setting, and primary position of
oncology nurses serve as significant predictors of attitudes and perceptions as measured
by the modified Nurse’s Attitude Survey (NAS)?
E. Definition of Terms
The key terms used throughout the research were operationalized and defined as
follows:
Oncology Nurses
Conceptual definition: A person skilled or trained in “treating human responses of
patients and families with cancer diagnoses or who are at risk for developing cancer. It
encompasses the role of direct caregiver, educator, consultant, administrator, and
investigator” (Oncology Nursing Society [ONS], 2004, p. 7).
Operational definition: Registered nurses (RNs) who are members of the
Oncology Nursing Society (ONS) who reside in the United States only, who permit ONS

10

to release their addresses, who self-report that they are employed full, or part-time, and
self-report their primary functional area as patient care or research and self-report a
primary position other than researcher/principal investigator.
Attitudes
Conceptual definition: “Summary evaluations of objects (e.g., oneself, other
people, issues, etc.) along a dimension ranging from positive to negative” (Petty,
Wegener, & Fabrigar, 1997, p. 611). The evaluations of these psychological objects are
captured in such attribute dimensions as good-bad, harmful-beneficial, pleasantunpleasant, and likable-dislikable (Ajzen, 2001; Ajzen & Fishbein, 2000). Attitudes are
made up of the beliefs that persons accumulate over their lifetimes (past experiences).
Operational definition: For this study, attitude was measured as the mental
position oncology nurses have with regard to the importance of conducting clinical
research in oncology. Specifically, their agreement or disagreement with statements that
clinical research improves patient care, is important for future standards of care in
oncology, encourages patients’ to participate in research, and the patients’ preferences to
be treated on a clinical trial, as measured on the NAS (Burnett, et al., 2001; see Appendix
A).
Perceptions
Conceptual definition: A representation of one’s reality, with a process of
interpreting information from sensory data and memory, that gives meaning to one’s
experience and influences one’s behavior (King, 1981).
Operational definition: Perceptions were measured as oncology nurses’
perceptions of patients’ understanding of cancer clinical trials, treatment of their cancer,

11

and their desire for information. Specifically, the nurse’s agreement or disagreement with
statements that patients are well informed regarding participation in clinical trials,
patients’ awareness that their treatment is part of a research protocol, patients’ understand
their treatment plans and prognoses, and patients desire to be informed as reported on the
NAS (Appendix A).
Cancer Clinical Trials
Conceptual definition: A type of research study that tests how well new medical
approaches work in people. These studies test new methods of screening, prevention,
diagnosis, or treatment of cancer (NCI, 2006). This includes any study that is provided in
the context of a research protocol, which has been approved by an Institutional Review
Board (IRB) and where a patient has signed an informed consent document. This includes
Phase I, II, III, and IV clinical trials.
Operational definition: A cancer clinical trial was defined as any study testing a
method of cancer treatment. Moreover, a study that is provided in the context of a
research protocol, which was approved by an IRB and patients have signed informed
consent documents. This includes Phase I, II, III, and IV clinical trials.
F. Assumptions and Limitations
Assumptions
The following assumptions were made:
1. There is variation among individual nurses’ knowledge regarding cancer
clinical trials.
2. There is no deceit or coercion, when nurses provide patients with information
and education regarding cancer clinical trials.
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3. Nurses responded honestly to all questions.
Limitations
The limitations of the study were:
1. Response bias may have existed using a survey method of data collection
(Dillman, 2000). It is unknown if people who responded to the survey may be different
from those who do not.
2. Individuals may have provided socially desirable responses. They may have
responded in a particular manner, regardless of what is a fair representation of their
attitudes or perceptions.
3. The sample of oncology nurses who were recruited from the ONS membership
may not represent all cancer nurses in the nation.
G. Significance
Clinical trials are essential to bring potentially beneficial basic research into
clinical practice and provide new methods of screening, prevention, diagnosis, or
treatment of cancer (Grunfeld, et al., 2002; NCI, 2006). In the U.S., very small
percentages (2-4%) of adult cancer patients participate in clinical trials (Lara, et al., 2001)
despite estimates that 12-44% of patients are eligible (Morrow, et al., 2004). Therefore,
there are more patients who could, but do not, participate in cancer clinical trials. This
shortage of clinical trial participants compromises the generalizability of findings and
delays development and adoption of new cancer treatments (Barrett, 2002). The delays
potentially could be detrimental to patients with a cancer diagnoses.
Oncology nurses have a key role in the clinical and research settings by serving as
direct caregivers, patient advocates, educators, counselors, as well as facilitators of
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clinical trials. As such, nurses have a major role in cancer clinical trials, yet not much is
known about their attitudes and perceptions on this subject. Only one study was reported
addressing nurses’ attitudes toward cancer clinical trials. Burnett et al. (2001) addressed
nurses’ attitudes toward cancer clinical trials in a comprehensive cancer center. The
investigators conducted a descriptive study with a 59-item self-report survey. The
objective was to identify nurses’ attitudes and beliefs toward cancer clinical trials and
their perceptions about factors influencing patients’ participation. Four hundred
seventeen nurses employed at a NCI-designated cancer center were surveyed, and 250
nurses (60%) responded. The authors found 96% of nurses reported that participation in
clinical trials is important to improving standards of care; however, only 56% of nurses
believed that cancer patients should be encouraged to participate in trials and 35% of
nurses reported that they would prefer treatment in a clinical trial if they had cancer.
This discrepancy is alarming considering that patients considering enrollment into
a clinical trial or presently are enrolled in one, receive important information about
treatment options from nurses. Additionally, NCI investigators found that many cancer
patients may not know what to ask, but, when they do, they are more likely to ask a nurse
than a physician (Nealon, Blumberg, & Brown, 1985). Oncology nurses’ attitudes and
perceptions are important factors that impact upon the nurses’ role in patient care.
Additionally, attitudes and perceptions impacts professional nursing issues, such as
nursing practice and nursing education. Nurses’ attitudes and perceptions regarding
cancer clinical trials ultimately may dictate their behaviors towards patients enrolled in or
contemplating enrollment in such trials. By investigating oncology nurses attitudes and
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perceptions toward cancer clinical trials this, study begins to assess the behavior of
oncology nurses towards cancer patients.
There is a paucity of research that addresses nurses’ attitudes and perceptions
towards clinical trials. This is curious, since nurses administer the experimental agents
used in clinical trials and provide direct care for these patients and their families. Most
literature regarding attitudes and perceptions of cancer clinical trials has focused on the
attitudes and understanding of physicians, patients, and the public (Cassilith, Lusk,
Miller, & Hurwitz, 1982; Comis, Miller, Aldigé, Krebs, & Stoval, 2003; Daugherty et
al., 1995; Ellis, Bulow, Tattersall, Dunn, & Houssami, 2001; Meropol, et al., 2003).
There is an important gap in knowledge regarding oncology nurses’ attitudes and
perceptions towards cancer clinical trials, the clinical trial process, and informational
need of potential research participants.
It is hoped that the results gained from this study will begin to close the gap in
knowledge and add to nurses’ understanding of clinical trials. This study potentially
identified discrepancies between the majority of nurses’ reporting that research is
important for advancing oncology standards of care and the smaller number who actually
recommend a research protocol to a patient.

CHAPTER II: REVIEW OF THE LITERATURE
The following review of the literature provided the theoretical and research
background for the issues that are addressed by the research questions. Despite an
extensive literature search of published works (CINAHL, MEDLINE, PsycINFO, EBM
Reviews, Health and Psychosocial Instruments database, ProQuest Digital Dissertations),
with Medical Subject Headings (MeSH) search terms, “nurses’ attitudes”, “nurses’
perceptions’”, and “cancer clinical trials”, only one study was found regarding nurses’
attitudes and perceptions of cancer clinical trials (Burnett et al., 2001). Consequently, this
literature review consists mainly of findings from related studies.
First, the organizing framework that guided this study is discussed, as well as a
review of healthcare literature incorporating the framework. Additionally, its relevance to
the proposed research explained. Next, a review of literature pertaining to attitudes and
perceptions related to clinical trials is discussed. Finally, the role of the oncology nurse in
the context of the care of patients enrolled in, or contemplating enrollment into, cancer
clinical trials is explained.
A. Organizing Framework
Ajzen’s and Fishbein’s (1980) Theory of Reasoned Action (TRA) provides the
framework that guided this study. The roots of the theory come from the field of social
psychology. Social psychology attempts, among other things, to explain how and why
attitude impacts behavior. Beginning in the 1930s, psychologists began to argue actively
about what components should comprise the attitude concept. Although there was
agreement that all attitudes contain an evaluative component, theorists disagreed about
whether beliefs (cognitions) and behaviors should be included within the attitude concept.
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The prevailing view among cognitive social psychologists was that “attitude” has both
affective and belief components and that attitudes and behavior should be consistent (e.g.,
people with positive attitudes should behave positively toward the attitude object; Ajzen
& Fishbein, 1980).
Social psychologists theorized that attitude included behavior and cognition and
that attitude and behavior positively were correlated. In 1935, Gordon Allport proposed
that the attitude-behavior concept was multi –dimensional, rather than unidimensional, as
previously thought (Allport, 1935; Azjen & Fishbein, 1980). Attitudes, as part of the
attitude-behavior concept, are multi dimensional systems consisting of beliefs about the
attitude object, feelings about the attitude object, and action tendencies toward the object
(Azjen & Fishbein, 1980).
One of the most famous early studies conducted by sociologist Richard LaPiere,
was studying if people behave consistently with their attitudes. LaPiere traveled across
the United States with a Chinese couple. The group stopped at over 200 hotels and
restaurants, where the Chinese couple was refused service at only one location. Six
months later, LaPiere wrote to these same establishments inquiring as to whether or not
they served Chinese guests. The responses he received indicated that 92% of the
establishments did not accommodate Chinese guests (LaPiere, 1934). LaPiere concluded
that different sets of social forces influenced attitudes and behaviors. This showed a
contradiction between the attitude responses to the letter and the actual behavior toward
the Chinese couple (Fazio & Roskos-Ewoldsen, 1994). This study demonstrated that,
attitude was not a good predictor of behavior. By the late 1960s, social psychologists no
longer believed they had a theory to explain the relationship between attitude and
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behavior. It was in this context that Ajzen and Fishbein created the Theory of Reasoned
Action (1967). The theory proposes that personal attitudes have a major influence on the
intent to engage in different behaviors (Ajzen & Fishbein, 1980). The theory views men
and women as a rational organisms utilizing information at their disposal to judge,
evaluate, and decide his course of action. Therefore, the intent towards choosing a given
behavior is a function of an individual’s attitude towards the behavior.
Attitudes are composed of the beliefs that individuals accumulate over their
lifetime. Some beliefs are formed from direct experience, some are from outside
information, and others are inferred, or self-generated. However, only a few of these
beliefs actually influence attitude. These beliefs are called “salient beliefs” and are the
“immediate determinants of a person’s attitude” (Ajzen & Fishbein, 1980, p. 63). An
attitude, then, is an individual’s salient belief about whether the outcome of their actions
will be positive or negative. If individuals have positive salient beliefs about the outcome
of their behavior, then they are said to have a positive attitudes about the behavior. And,
vice-versa, if individuals have negative salient beliefs about the outcome of their
behavior, they are said to have negative attitudes. The beliefs are rated for the probability
that engaging in the behavior will produce the believed outcome. This is called the
“belief strength.” These two factors, belief strength and the evaluation, are then
multiplied to give the attitude (Ajzen & Fishbein).
The TRA attempts to predict human behavior, based on concepts of personal
beliefs, attitude towards the behavior, perceived beliefs of others, and subjective norms
(see Figure 1).
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Figure 1. Model of reasoned action. (Ajzen & Fishbein, 1980)
Therefore, an individual’s belief could ultimately determine one’s attitudes,
intentions and behaviors. In combination, attitude toward the behavior, subjective norm,
and perception of behavioral control lead to the formation of behavioral intention (Ajzen,
2001). As a general rule, the more favorable the attitude and subjective norm, and the
greater the perceived control, the stronger should be the person’s intention to perform the
behavior in question. Finally, given a sufficient degree of actual control over the
behavior, people are expected to fulfill their intentions when the opportunity arises
(Ajzen, 2001). A person’s intention, then, becomes a function of personal and social
influence. Both attitudinal and subjective factors are important determinants of intention,
but the relative weight of each component varies with the individual (Ajzen & Fishbein,
1980). As suggested by its name, the TRA proposes that people engage in a deliberate
and thoughtful process in deciding how to behave (Sanbonmatsu & Fazio, 1990).
This study focused on the attitudes of oncology nurses towards cancer clinical
trials and their perceptions of patient understanding and reasons for patient participation
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in clinical research. Concepts of the theory define the nurse’s own beliefs, as well as, the
perceived beliefs of those groups that are in a position to influence the ideas and actions
of the nurse. These beliefs and actions pertain to the nurse’s relationship with the patient
contemplating enrollment or already enrolled in a cancer clinical trial. Therefore, the
combination of the nurse’s beliefs and the group belief could lead one to action,
depending upon which set of beliefs are more valued (or is perceived to lead to a positive
outcome) by the nurse, thus forming an attitude on the part of the nurse.
One way to begin to assess the actions of nurses towards patients is to investigate
their attitudes. The nurses’ attitudes regarding cancer clinical trials may ultimately dictate
their behavior towards patients enrolled in or contemplating enrollment in a cancer
clinical trial. Within the practice of oncology nursing, these behaviors can include direct
patient care, coordination of care, patient education, and patient advocacy.
In this study the measurement of attitudes (and perceptions) were assessed via a Likert
scale to discern positive and negative attitudes. Having negative attitudes towards cancer
clinical trials may impact the nurse’s objectivity in his/her role as patient educator or
patient advocate and determine the nurse’s behavior in these situations. Nurses perceive
their roles differently from other healthcare professionals in that, in addition to focusing
on clinical judgments and decision making, they concentrate on patient advocacy and
caring (Krisjansdottir, 1992). This caring focus enables nurses to ensure adequate
communication with patients about treatment regimens. Nurses may be more aware of
patients’ attitudes towards clinical trial research, because of the unique patient-nurse
relationship. Nurses’ attitudes may influence patient’s opinions regarding participation
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and may reflect patients concerns in this area. The nursing role and type of caring focus
outlined above are all part of the nurse-patient relationship.
B. The Use of the TRA in Health Care Literature
Nursing Research Examining Attitudes
In nursing research the TRA has been shown to be a viable theory examining the
attitudes of nurses and patients. Renfroe, O’Sullivan, and Mcgee (1990) developed a
causal model, using the components of the TRA, for explaining nursing documentation
behavior. They utilized the TRA to assess the relationship of nurses’ attitudes, subjective
norms, and behavioral intentions to their documentation behaviors. Subjective norm is
defined as a “person’s assessment of whether or not people important to him or her feel
the behavior should be performed” (Ajzen, 2001, p. 32). Behavioral intention is related to
attitudes and subjective norms. The more favorable the attitude and subjective norm, and
the greater the perceived control, the stronger the person’s intention should be to perform
the behavior in question (Ajzen). The purpose of the study was to develop and test the
TRA that explained documentation behavior of nurses. A convenience sample of all staff
nurses (N = 108) at three different hospitals, on all units (excluding emergency room,
operating room, labor and delivery, and psychiatric units) within three hospitals in the
Southeast was used. The authors collected data using a questionnaire that they developed
to measure each component of the causal model, attitude, subjective norm, behavioral
intent, and documentation behavior. Prior to shift report, each nurse completed the
questionnaire and returned it to investigators. After the shift, the investigators returned to
the unit to score the documentation for one patient assigned to each nurse that shift.
Documentation behavior “was based on what should be documented in any hospitalized
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patient’s chart during an eight hour shift” (Renfroe, O’Sullivan, and Mcgee, 1990, p.52).
Attitude toward documentation did not relate significantly to intention to document
optimally. Subjective norms had a significant effect on behavioral intent. Attitude and
subjective norm accounted for 46.1% of the variance in behavioral intent. Behavioral
intent had a significant effect on documentation behavior, accounting for 15.2% of the
variance. It appears that subjective norm, which is the influence of others, directs the
intention to document and thus relates to subsequent documentation. The authors’
recommendations for practice, based on the study findings, include the communication of
high ideals and expectations of important others to the staff nurse to improve the
documentation quality.
Using the TRA as a theoretical framework for their study, Stuppy, Armstrong,
and Casals-Ariet (1998) examined the attitudes of health care providers, medical and
nursing students (N = 513) towards tattooed adults and adolescents. This was a
descriptive correlational, comparative study, with a demographic form and the Armstrong
Tattoo Scale (ATS) distributed to convenience samples of physicians, registered nurses,
licensed vocational nurses, and medical and nursing students. The ATS is a semantic
differential scale consisting of 16 contrasting adjectives representing beliefs about
persons with tattoos. Items for the ATS were generated from the clinical experience of
the investigators, interviews with tattoo artists, tattooed people, and from the literature.
Adjective pairs on the ATS included such items as ugly-beautiful, impulsive-deliberate
and crude-refined. Each item was scored from 1 (strongly agree at the negative end) to 7
(strongly agree at the positive end). Data were coded so that a higher score reflected more
positive attitudes. Possible scores ranged from 16 to 112, when responses to all items
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were summed. An expert panel of doctorally prepared faculty investigators and
sociologists reviewed the instrument for content validity. A pilot study with 161 nursing
students determined initial construct validity. Exploratory principal component analysis
indicated that 10 items represented an evaluation dimension and six items related to an
activity dimension about attitudes toward tattooed persons. Respondents were asked to
record their attitudes towards five groups of people. Groups to be rated were professional
men, nonprofessional men, professional women, nonprofessional women and adolescents
(13–18 years old). The type of tattooed person to be rated was listed as the heading for
the 16 item ATS (e.g., “Professional women who have tattoos are . . .”). For the five
groups internal consistency reliability of the ATS ranged from a Cronbach’s alpha of 0.92
to 0.95. The authors found no respondent group had mean scores reflecting a positive
attitude towards tattooed persons. This study suggests that tattooed persons, especially
adolescents, may be at risk of being negatively perceived, when they seek health care.
Clarke and Aish (2002) explored the health beliefs and attitudes of a group of
smokers with vascular disease who participated in a smoking cessation program (Group
1) and a group who declined participation (Group 2). The authors used Ajzen and
Fishbein’s TRA, Keeney’s Expected Utility Decision Theory (Keeney, 1992), and
Prochaska and DiClemente’s Transtheoretical Model of Change (DiClemente, 1997) to
describe the influence of this smoking cessation program on beliefs and attitudes about
smoking in Group 1. Smokers completed a smoking beliefs questionnaire with vascular
disease at baseline and after 13 weeks of a smoking cessation intervention. Smokers who
did not want to participate in the smoking cessation program also completed this
questionnaire (Group 2). Statistically significant differences differentiated people who

23
enrolled in the smoking cessation program from those who did not. Subjects in Group 2
smoked less per day, were less educated, were less often diagnosed as having peripheral
arterial disease, were found to be more in the precontemplation stage of change in
smoking cessation, cared more about what their physician and family thought they should
do, and perceived themselves to be at less risk for developing more severe circulatory
problems if they did not quit smoking. After 13 weeks, participants in both Groups 1 and
2 were found to smoke significantly less per day. No support was found for the
expectation that the smoking intervention would influence stage of change in smoking
behavior or attitudes and beliefs about the risks of smoking to the participants’ health
after 13 weeks.
Nursing Research Examining Behaviors
The TRA has also been used in nursing research as a basis for studying the
behaviors of nurses, healthcare workers, students, and patients. Selected college students
(n = 256) and sexually transmitted disease (STD) clinic patients (n = 71) of the same age
were compared for knowledge about AIDS, use of condoms, sexual behaviors and
intentions to engage in various sexual practices (Strader & Beaman, 1991). The TRA
model was used to elicit beliefs about condom use and significant referents that influence
decisions on condom-use. Of the 256 college students, 87% were sexually active. College
students had significantly fewer sexual partners in a 30-day period than STD patients, but
in a 6-month period the mean number of sexual partners was the same for both groups.
Significant difference was found in frequency of condom use for subjects with more than
one partner. Among the college student sample, 60% did not use condoms compared with
32% of STD patients. Eighteen percent of college students reported intention to engage in
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anal intercourse. No STD patients reported such intention. No statistical difference was
found between groups on overall knowledge about AIDS and both groups manifested
adequate knowledge of basic AIDS-related facts. Significant differences between groups
were found in rank order of beliefs about using condoms as well as the referents that
influenced decision-making. Beliefs about disease, pregnancy, worry, and the influences
of sexual partners and friends had the strongest impact on college students. Sexual
partners and mothers had a strong influence on STD patients’ decisions-making, while
“disease,” “pregnancy,” “decreases feeling” and “decreases partner’s pleasure” were
among the beliefs influencing condom use.
Miller, Wikoff, and Hiatt (1992) tested five variables of the TRA. The variables
measured were attitudes, perceived beliefs of others, motivation to comply, intentions,
and compliance behavior. The purpose of the study was to test the sufficiency of these
variables to predict compliance with the medical regimen of hypertensive patients (N =
56). The subjects were a convenience sample of patients at an outpatient Veterans
Administration (VA) Medical Center hypertensive clinic. The authors used the Miller
Attitude Scale (Miller, Wikoff, McMahon, Garrett, & Johnson, 1982) to measure
favorable and unfavorable attitudes towards performing medical regimen prescriptions.
The Perceived Belief of Others Scale (Miller, Johnson, Garrett, Wikoff, & McMahon,
1982) was used to assess the subjects’ beliefs about which prescriptions of the medical
regimen people thought were most important to them and to which they should be
compliant. The Motivation to Comply Scale (Ajzen & Fishbein, 1980) was used to
measure motivation to comply with the regimen’s prescription. Intentions were measured
by the Health Intention Scale designed to assess subjects’ intentions to perform the
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medical regimen. Finally, behavior was measured by the Health Behavior Scale which
measured subjects’ compliance to the medical regimen. The authors reported the results
using the Pearson Product moment correlations among the five variables (attitudes,
perceived beliefs of others, motivation to comply, intentions, and compliance behavior).
The results demonstrated the TRA sufficient for the prescriptions of diet, smoking,
activity and stress, but not for medication. Findings indicated that compliance behavior
was directly influenced by intention which, in turn, was influenced directly by attitude
and motivation to comply and, indirectly, by perceived beliefs of others and were
mediated by motivation to comply with the prescriptions of diet, activity, smoking, and
stress. For the medication prescription, attitude and motivation to comply directly
influenced regimen compliance.
Dunkle and Hyde (1995) used the TRA to identify factors that influence physical
therapist and registered nurse (RN) students’ intentions toward working with elderly
individuals. Based on the TRA a survey instrument was developed to assess student
intention to work with elderly individuals and factors influencing this intention. Later
graduates were contacted to determine whether job selection matched intention. For all
students, factors influencing intention were students’ attitudes and students’ perceptions
regarding their families’ expectations about the students’ working with elderly persons.
Intention had a positive correlation with job selection. Important underlying beliefs
influencing students’ attitudes, include the advantages of getting to know elderly patients
and their families and caring for pleasant patients. The authors concluded that the results
support using a theory-based model to identify predictors of job selection among physical
therapist and nursing graduates.
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The TRA and the Theory of Planned Behavior (TPB), another theoretical model
by Ajken and Fishbein, were tested as predictors of health care workers’ glove use when
there is a potential for blood exposure (Levin, 1999). The TPB is an extension to the TRA
and includes and additional element of “perceived behavioral control,” in order to
account for situations where an individual has less than complete control over the
behavior. Perceived behavioral control indicates that a person’s motivation is influenced
by the perceived difficulty of the behaviors, as well as the perception of how successfully
the individual can, or can not, perform the activity. If individuals hold strong control
beliefs about the existence of factors that will facilitate a behavior, then they will have
high perceived control over a behavior. Conversely, individuals will have a low
perception of control if they hold strong control beliefs that impede the behavior (Ajzen,
1985). Levin (1999) surveyed a random sample of nurses and laboratory workers (N =
527) who completed a 26-item questionnaire. Using structural equation modeling
techniques, intention, attitude, and perceived risk were significant predictors of behavior.
Perceived control and attitude were the significant determinants of intention. The TRA
was the most parsimonious model, explaining 70% of the variance in glove use behavior.
The TPB was a viable model to study behavior related to glove use and reducing
workers’ risks to blood borne diseases.
Poss (1999) developed a Spanish-language, quantitative research instrument
designed to study Mexican migrant farm-workers participation in tuberculosis screening.
The instrument was pilot tested with19 Mexican migrant farm-workers to study their
tuberculosis screening behaviors. The Tuberculosis Interview Instrument (TII) was
developed from the results of a qualitative study and concepts from a theoretical
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framework consisting of a combination of the Health Belief Model (HBM) (Becker,
Radius, & Rosenstock, 1978; Rosenstock, Strecher, & Becker, 1994) and the Theory of
Reasoned Action (TRA). After its development, the TII was subjected to translation and
back-translation procedures to insure the equivalency of the English and Spanish
versions, and it was reviewed for content validity.
In another study, Poss (2000) recruited a convenience sample of Mexican migrant
farm workers (N = 206), after a presentation of a tuberculosis education program,
participants were followed during the administration and reading of tuberculosis skin
tests. The purpose of the study was to analyze the relationship between variables
(susceptibility, severity, barriers, benefits, cues to action, normative beliefs, subjective
norm, attitude, and intention) from the HBM and the TRA and participation by Mexican
migrant farm workers in a tuberculosis screening program. Participants were interviewed
in Spanish by the principal investigator, using the TII. Most subjects were male, aged 18–
27 years, and had less than a sixth-grade education. Of the 206 subjects, 152 (73.4%)
received the skin test, 149 (98%) had the skin test read, and 44 (29.5%) had positive skin
tests. Based on logistic regression analysis, the model that best predicted intention
included cues to action, subjective norm, susceptibility, and attitude. Participation in
screening was best predicted by a model containing only two variables, intention and
susceptibility. In this study, logistic regression analysis revealed that a more
parsimonious model than the full HBM and TRA model accurately predicted both
intention and behavior. Kleier (2004) tested the TRA to determine the behavior of nurse
practitioners (NPs) regarding teaching testicular self-examination (TSE). The researcher
utilized an instrument, developed by Minnick (1980), to explore relationships between
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variables that applied the concepts in the TRA. The variables were attitudes, perceptions
of and motivation to comply with opinions of others, behavioral intention to teach TSE,
and TSE teaching behavior. A cross-sectional, exploratory, mailed survey was used to
survey a random sample of 1,490 members of the American Academy of Nurse
Practitioners, 621 NPs responded. After eliminating surveys that were not usable because
of missing data, final analyses were carried out on 532 surveys, for a response rate of
36%. The author concluded that NPs had positive attitudes toward teaching TSE and
were engaged in such teaching. They perceived that other NPs, physicians, and patients
also valued TSE teaching. Attitude, perception of and motivation to comply with the
opinions of significant others, and behavioral intention were associated with each other
and predictive of TSE-teaching behavior. The findings supported the explanatory and
predictive ability of the TRA.
Nonresearch Articles
Additionally, review articles have been written citing the TRA in the development
of models to predict health behaviors. Fleury (1992) reviewed the primary motivational
theories that were used to explain cardiovascular risk reduction. Specifically, the
application of the Heath Belief Model, Heath Promotion Model, the TRA, TPB, and SelfEfficacy Theory to the initiation and maintenance of cardiovascular health behavior was
addressed.
In evaluating the behavioral aspects of clinical trials, Morrow, et al. (1994)
reviewed the literature on accrual in oncology clinical trials to characterize the extent of
the problem of low accrual, identify reasons for it, and suggest ways to improve it. The
authors examined four theories of health behavior (the Health Belief Model, Subjective
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Expected Utility Theory, Protection Motivation Theory, and the TRA) and found that all
suggest central concepts involved in understanding patient health-related behavior.
McGahee, Kemp, and Tingen (2000) developed a model for smoking prevention
in preteen children, because they determined the lack of a well-defined theoretical basis a
weakness in the research conducted on smoking prevention programs designed for
preteen children. The authors used the TRA as well as other literature to develop their
model.
Finally, Poss (2001) discussed the development of a new model developed as the
theoretical framework for an investigation of the factors affecting participation by
Mexican migrant workers in tuberculosis screening. The new model was developed by
synthesizing the Health Belief Model (HBM) and the TRA. Intention to take part in
tuberculosis screening was best explained by a model containing four variables:
subjective norm, attitude, susceptibility, and cues to action (operationalized as attendance
at an educational program). The best model for predicting behavior (actual participation
in screening) required only two variables: intention and susceptibility. In both cases,
variables derived from both the HBM and the TRA were necessary to predict the
dependent variable.
C. Attitudes and Perceptions
Attitudes and perceptions are related concepts. As previously defined (in chapter
1), attitudes are evaluations of psychological objects (e.g., oneself, other people, issues,
etc.) captured in such attribute dimensions as good-bad, harmful-beneficial, pleasantunpleasant, and likable-dislikable (Ajzen, 2001, Ajzen & Fishbein, 2000).
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Perceptions are a representation of one’s reality, with a process of interpreting
information from sensory data and memory, which gives meaning to one’s experience
and influences one’s behavior (King, 1981). It is the basis by which one’s opinions or
views are formed and, thereby, give rise to actions.
In the nurse-patient relationship, perception is a crucial component of the nurse’s
assessment of the patient and clinical situation (King, 1981). King states that nursing is “a
process of human interactions between nurse and client whereby each perceives the other
and the situation; and through communication, they set goals, explore means, and agree
on means to achieving goals” (King, 1981, p. 144). The perceptions of the nurse must be
in agreement with the patient’s perceptions for mutual goal setting to occur. Only then
can patients collaborate with the nurse to set goals, explore the means and agree on the
strategies to attain mutual goals. The nurse must perceive accurately the patient and
clinical situation to work toward a common goal.
Attitudes are perceptions that persons accumulates over their lifetime (past
experiences). King also states that perceptions are related to factors such as past
experiences and educational background (King, 1981). This suggests that perceptions are
subjective in nature and, consequently, nurses’ perceptions may be very different from
the patients’ perceptions. In this study the subjective nature of perception was explored as
oncology nursing experience and education were analyzed as predictors that could
influence perceptions and attitudes. Additionally, attitudes guide behavior, the more
favorable the attitude and subjective norm, and the greater the perceived control, the
stronger the person’s intention to perform a behavior (Ajzen & Fishbein, 1980).
According to King (1981), perceptions also influence behavior. As an example, the nurse
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and patient meet in some situation, perceive each other, make judgments about each
other, take some mental action, and react to each one’s perceptions of the other (Gonot,
1989; King, 1981). When interactions lead to transactions, “goal attainment behaviors”
are exhibited (King, 1981, p. 60). Underlying the interaction process is that reciprocally
congruent behavior, which the behavior of one person influences the behavior of the
other and visa versa (Gonot, 1989; King, 1981). Therefore, individuals’ attitudes and
perceptions influence their behavior.
As stated above, attitudes and perceptions are related and interconnected
concepts. Beginning with experience, events occur, and those events have a real or
imagined vital and affective meaning to individuals. That experience produces a set of
structured or unstructured beliefs and expectations. The beliefs and expectations have a
motivational force. The objects from which an individual forms a belief are that which an
individual experiences. That which one experiences is, so to speak, the objective term of
the process. The affective motivations and reactions to experience are the subjective
terms of the process. These are the attitudes that emerge. One’s attitudes consciously or
unconsciously determine how one will perceive like experiences in the future (G. Husted,
February 6, 2006, personal communication).
Attitudes and Decision Making
Attitudes were also studied as a base for decision-making in the psychology
literature. Sanbonmatsu and Fazio (1990) examined the role of attitudes in memory-based
decision-making. They conducted two experiments to represent some of the conditions
under which attitudes guide memory-based decision making. Participants in both
experiments were undergraduates fulfilling a requirement for an introductory psychology
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course (Experiment 1, n = 98; Experiment 2, n = 270). Experiment 1 examined the effect
of fear of invalidity (a motivational variable) and time pressure (an opportunity variable)
on the likelihood that a memory-based decision will be guided by attitudes. The primary
dependent measure for both experiments was the participants’ decision as to which store
they would shop for a camera. The general description of one store, “Smith’s Department
Store,” was favorable with the exception of the camera department, which was
unfavorable. The other stores general description, “Brown’s Department Store,” was
unfavorable with the exception of the camera department, which was favorable. They
made the decision to purchase a camera under high or low time pressure, and under
conditions of high or low fear of invalidity. The results from experiment 1 revealed the
majority of participants (81 out of 98) evaluated Smith’s more positively than Brown’s. A
2 x 2 (fear of invalidity X time pressure) between subjects analysis of variance (ANOVA)
was performed on the subjects camera decisions. Participants’ low in fear of invalidity
were more likely to choose Smith’s than participants experiencing high fear of invalidity.
The authors concluded that as the motivation to make a correct decision or the
opportunity to access the relevant available knowledge decreases, the likelihood of an
attitude-based decision increases.
In contrast to Experiment 1, in Experiment 2, the participants explicitly were
instructed to form differentiated attitudes toward each department of each store, as well
as general attitudes toward each store. The difference between Experiment 1 and 2 was
with the participants in the differentiated attitude condition. As in experiment 1 the
majority of participants (231 out of 270) evaluated Smith’s more positively than
Brown’s. The participants’ camera shopping decisions were then evaluated using a 2 x 2
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x 2 (differentiation X fear of invalidity X time pressure) using between-subjects
ANOVA. The authors concluded that attitudes guide decisions, and hence behavior, by
affecting one’s appraisals (perceptions) of decision alternatives. Attitudes provide a ready
means of “sizing up” or appraising objects and events (Sanbonmatsu & Fazio, 1990, p.
620). In the context of decisions, the authors found attitudes provided a ready assessment
of choice alternatives and they enabled an individual to make a decision rapidly and
effortlessly. They also state that if a behavior were to be based on a number of specific
beliefs and attitudes, then measuring those beliefs and attitudes is an effective way of
predicting behavior.
Nurses’ Attitudes and Perceptions
The investigator was only aware of one study reported that addressed nurses’
attitudes toward cancer clinical trials. Burnett, et al. (2001) addressed nurses’ attitudes
toward cancer clinical trials in a comprehensive cancer center. They conducted a
descriptive study with a 59-item self report survey. The objective was to identify nurses’
attitudes and beliefs toward cancer clinical trials and their perceptions about factors
influencing patients’ participation in these trials. Four hundred seventeen nurses
employed at a NCI designated cancer center were surveyed, and 250 nurses (60%)
responded. The authors found 96% of nurses reported that participation in clinical trials is
important to improving standards of care; however, only 56% of nurses believed that
patients should be encouraged to participate in cancer clinical trials. In multiple
regression analyses, older age (40 years of age or older) and being a research nurse were
significant predictors of positive attitudes toward clinical trials. Work setting also was a
significant predictor of nurses’ perceptions of patients’ understanding of treatment.
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Research nurses had the highest mean score (23.2 out of 30) compared to intensive care
unit/bone marrow transplant (ICU/BMT) nurses, who had the lowest mean score (18.6
out of 30; p = 0.0001). Overall, nurses reported that an investigational therapy should
have at least a 50% chance of success prior to being offered to patients. The authors’
recommendations for future research were to replicate the study with other
comprehensive cancer center nurses, to conduct a study with nurses from settings other
than comprehensive cancer centers, to compare the findings between the groups, and to
study current nursing educational methods and models of nurse-physician interaction in
research settings.
In a descriptive study of oncology physicians’ and nurses’ attitudes of offering
clinical trial results to study patients, Partridge, et al. (2004) identified oncology nurses
and physicians through the Cancer and Leukemia Group B (CALGB) database [CALGB
is a federally funded network to conduct cancer clinical trials]. Surveys were mailed to
1,977 members and 796 (40.3%) responded. Responders included 125 (15.7%) nurses,
650 (81.7%) physicians, and 21 (2.6%) individuals who identified themselves as “other”
(psychologists, epidemiologists, etc). This study was primarily descriptive.
Approximately 62% of respondents reported offering results to patients less than onefifth of the time. Almost 79% of responders felt trial results should be offered to most
study subjects. Patients want to know trial results according to 72.4% of respondents, and
62.2% of them did not believe that routinely offering results would have a negative
impact on many patients. The study was limited by the use of a questionnaire that was not
prospectively validated (Partridge, et al., 2004). Additionally, nonresponse rates differed
among specialty groups. Fifty-two percent of nurses surveyed responded compared with
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42% of medical subspecialists, 35% radiation oncologists, and 33% surgeons (p<0.001
for all four groups, p = 0.0014 for physicians only). The authors state that future studies
should evaluate the process and effects of sharing results with study participants and they
developed a model that includes the views of all parties involved. They feel this type of
research may improve communication between health care providers and patients, and
increase patient satisfaction with the care received during a clinical trial (Partridge et al.,
2004).
In Greece researchers examined Greek nurses’ attitudes toward truth-telling
practices when working with cancer patients and their psychological status regarding the
difficulties they faced in their day-to-day communication with these patients (Georgaki,
Kalaidopoulou, Liarmakopoulos & Mystakidou, 2002). The researcher designed
questionnaire had 19 questions, including both multi-item scales and single item
measures. The response options were “yes,” “sometimes,” or “no.” The questionnaire
was mailed to head nurses in Athen’s oncology hospitals and oncology departments of
general hospitals. These nurses were asked to distribute it to their nurses. Two hundred
staff nurses were asked to participate, 148 nurses (74%) completed and returned the
questionnaire. The results revealed that 75.7% of respondents believed that only some
cancer patients should be told the truth of their diagnosis and prognosis and a larger
percentage (89.1%) believed that the truth should be told to relatives. Most respondents
(66.2%) reported that it is difficult to engage in open communication with the patients,
because their education did not provide sufficient training in communication skills.
Eighty four percent reported that they do not reveal that the disease is incurable, 58.1%
believed that only the patient’s physician should reveal the truth. These results indicated
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that although many Greek nurses believe that the patients should be informed and know
their condition, lack of training in communication skills is a major obstacle to achieving
this.
Chang (2004) conducted a review of the nursing literature of published works
(CINAHL, MEDLINE, PsycInfo, EBM reviews) exploring nurses’ perceptions of Phase I
clinical trials in pediatric oncology. The author found no literature related to this topic,
except for the one previously discussed by Burnett et al. (2001) that reported nurses’
attitudes toward adult clinical trials.
Patient, Public, and Physician Attitudes and Perceptions
Attitudes of patients and the public were evaluated in a study conducted over 20
years ago by Cassileth, Lusk, Miller, and Hurwitz (1982). One hundred and four patients
with cancer, 84 cardiology patients and a control group of 107 members of the general
public completed an anonymous self-report questionnaire consisting of 10 multiplechoice questions and one open-ended item. Respondents’ opinions on the purpose and
ethicality of clinical research were obtained. Responses to the questionnaire items did not
differ by each group (patients with cancer, cardiology patients, general public) nor by
demographic variables such as age or sex. Therefore, data were reported on the total
sample of 295 respondents. Seventy-one percent of respondents believed that patients
should serve as research subjects and 52% of respondents stated the main reason they
would participate in medical research would be to get the best medical care. Thirty-six
percent of respondents felt patients received better care when the treatment plan is
determined by their physician. Thirty-eight percent felt patients received better or equal
care when their treatment is based on a research protocol. A large percentage of
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respondents (70%) thought that physicians have prior knowledge of which one of the
investigated treatments is best. Since a large percentage expressed this belief, it can be
inferred that many people do not understand the nature of clinical trials. This is an area
where oncology nurses can assist patients with the information and education regarding
the purpose of clinical trials.
Patients’ Attitudes
Ellis et al. (2001) conducted a cross sectional survey of women (N = 545)
attending a breast clinic for screening mammography or diagnostic assessment plus
women with newly diagnosed breast cancer, the purpose was to assess attitudes toward
and willingness to participate in randomized clinical trials of breast cancer treatment. A
questionnaire was developed using information obtained from focus group interviews in
conjunction with a review of the literature. The questionnaire contained information from
the following areas:
1. Demographic data, including age, marital status, education, occupation,
ethnicity, and medical/allied health training.
2. The Hospital Anxiety and Depression Scale (HADS) a questionnaire that
contains seven items assessing symptoms of anxiety and seven items assessing
symptoms of depression (Moore et al., 1991; Zigmond & Snaith, 1983).
3. Women’s preferences for the amount of information they wish to receive from
their doctor using a three-item scale previously described by Cassileth, Zupkis,
Sutton-Smith (1980) and their level of involvement in clinical decision-making
using a five-item scale (Degner, et al., 1997; Degner & Sloan, 1992).

38
4. Knowledge about the need for clinical trials and about the manner in which
randomized clinical trials are conducted, which was measured using a 7-item scale
developed by the authors of the study.
5. Attitudes toward randomized clinical trials, which was measured using a 36item scale developed from focus group data and a review of the literature that
measured the impact of individual items on women’s willingness to participate in
randomized clinical trials on a seven-point Likert scale (7 = very likely to join a
trial, 4 = would not influence my decision, 1 = very unlikely to join a trial).
6. General willingness to participate in randomized clinical trials.
7. Reasons to consider joining/not joining a clinical trial.
The findings suggested that women who have a better understanding of issues about
clinical trials had more favorable attitudes toward clinical trials and were more willing to
consider participation.
Daugherty et al. (1995) conducted a pilot survey study of the perceptions of
cancer patients and their physicians involved in Phase I cancer trials. Thirty cancer
patients who had given informed consent to participate in a Phase I clinical trial and
eighteen oncologists were surveyed. Eighty-five percent of patients reported that they
participated in a Phase I trial, because of possible therapeutic benefit. Ninety-three
percent of patients said they understood all or most of the information provided about the
trial; however, only 33% were able to state the purpose of the trial in which they were
participating. The authors concluded that cancer patients who participate in Phase I trials
are strongly motivated by the hope of therapeutic benefit. Cancer patients who participate
in Phase I trials appeared to have an adequate knowledge of the risks of experimental
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therapy. However, only a minority of patients appear to have an adequate understanding
of the purpose of Phase I trials.
Comis, et al. (2003) conducted a study to understand the attitudes of American
adults toward participation in cancer clinical trials. A national probability sample of
1,000 adults aged 18 or older living in noninstitutional settings were interviewed via
telephone by Harris Interactive. The results indicated that the primary problem with
accrual is not the attitudes of patients, but the loss of potential participants is the result of
the unavailability of an appropriate clinical trial. The authors also state that many patients
hold mistaken views of the nature of clinical trials, and that many significantly
overestimate the efficacy of standard therapies in making their decisions.
In a study describing and comparing the perceptions of cancer patients and their
physicians regarding Phase I clinical trials, Meropol et al. (2003) surveyed eligible
patients who were offered Phase I trial participation, had accepted, but had not yet begun
treatment (n = 328). Each patient’s physician also was a study subject (n = 48). Patients
and physicians completed questionnaires with domains including perceptions of potential
benefit and harm from treatment (experimental and standard), relative value of quantity
and quality and length of life, and perceived content of patient-physician consultations.
Patients had high expectations regarding treatment outcomes (e.g., median 60% benefit
from experimental therapy). Patients predicted a higher likelihood of both benefit and
adverse reactions from treatment (experimental and standard) than their physicians (p <
0.0001 for all comparisons). Although 95% of patients reported that quality of life was at
least important as length of life, only 28% reported that changes in quality of life with
treatment were discussed with their physicians. In contrast, 73% of physicians reported
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that this topic was discussed (P < 0.0001). The authors conclude that this discrepancy in
reports of consultation content, particularly given patients’ stated values regarding quality
of life, raise the possibility that such communication is suboptimal.
There were other studies which suggest that patient understanding about clinical
trials can be improved through the provision of greater amounts of information
(Aaronson et al., 1996; Davis, Nealon, & Stone, 1993; Simes et al., 1986).
The study by Aaronson et al. (1996) is the only study which used a nursing
intervention to evaluate improving the informed consent process. The authors evaluated a
strategy of providing additional information to patients considering entry into Phase II or
III trials at the Netherlands Cancer Institute (N = 180). Patients were randomized to the
standard consent interview, or the standard interview followed by a telephone call several
days later from a clinical trials nurse to further discuss the information provided in the
consent interview. As compared with patients provided only with verbal and written
information from their treating physician (control group), those who also received
information from an oncology nurse (intervention group) were better informed about the
potential side effects of the proposed treatment, the clinical trial context in which the
treatment was to be given, and many of the essential details of the clinical trial. The
largest gains were observed in the percentage of patients aware of randomization
procedures and of the right to withdraw from the trial. Patients in the intervention group
were slightly more likely to decline participation (24% vs. 13%). The authors conclude
that this type of nursing intervention, as an adjunct to established informed consent
procedures had a positive effect on cancer patients’ awareness of the most salient issues
that surround the Phase II and III clinical trials in which they are asked to participate.
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While this trial occurred outside the U.S., this institution is an active member of the
national clinical trials group in the U.S. The nursing intervention that was described was
consistent with U.S nursing practices. This study represented a beginning attempt at
formalizing a unique role of the nurse in the informed consent process, as focused on
knowledge and education of patients.
Davis et al. (1993) randomized patients considering entry into Phase III clinical
trials to receive either standard information about clinical trials or standard information
plus a NCI booklet explaining clinical trials. Two hospitals tested the booklet with
patients who were eligible for a specific clinical trial, and two hospitals tested the booklet
with patients who were theoretically eligible for a clinical trial (with a cancer site and
stage for which a trial existed). Patients were assigned randomly: 203 experimental
subjects received the booklet, and 194 control subjects were not given the booklet until
after completing a 2-week post-test examining attitudes, knowledge, and beliefs about
clinical trials. Overall patients who received the booklet were more knowledgeable about
clinical trials, but there were no differences in participation rates.
Simes et al. (1986) randomized patients eligible for entry into randomized
chemotherapy trials to ether full or individualized information disclosure. Patients in the
full disclosure group had significantly greater knowledge about their illness and treatment
and about the research plan. There were no significant differences between groups,
although patients in the full disclosure group were a slightly more likely to decline trial
participation (18% vs. 7%).
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D. Oncology Nurses Role
Oncology nursing practice is delineated by the ONS in “Statement on the Scope
and Standards of Oncology Nursing Practice” (ONS, 2004). Oncology nursing
encompasses the role of direct caregiver, educator, consultant, administrator, and
investigator (ONS, 2004). Additionally, oncology nurses act as patient guides and
advocates by “assisting patients and families to seek information, ensuring informed
consent regarding treatment decisions, and promoting the maximal level of patientdesired independence” (ONS, 2004, p. 8). An ONS professional performance standard of
relevant to this study is standard five, ethics, which states, “The oncology nurse uses
ethical principles as a basis for decision making and patient advocacy” (ONS, 2004, p.
37).
Oncology Nurses’ Role in Clinical Trials
Nurses have a critical role with informed consent. They help patients become
more effective partners in the clinical trial decision-making process by explaining how
scientific advances are made, describing the patients’ roles and rights in the studies, and
providing sources for more information (Sadler et al., 1999).
Patient advocacy includes assisting patients in defining their own goals and
purposes for participating in a clinical trial (McEnvoy, Cannon, & MacDermott, 1991).
Depending upon the practice setting, oncology nurses have responsibility for recruiting
participants, explaining informed consent, monitoring participant responses, documenting
data, and serving as a liaison with multidisciplinary teams (Liaschenko & DeBruin,
2003). This demonstrates the multifaceted role of oncology nurses in the conduct of
clinical trials. The ONS (1998) position statement on cancer research and cancer clinical
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trials states that “coordination of clinical trials (e.g., coordination of clinical sites,
development of standardized treatment orders, symptom management, patient education
and advocacy, facilitation of informed consent, assistance with participant accrual and
retention) is best accomplished by RNs who have been educated and certified in
oncology nursing” (p. 973). As clinicians, nurses are expected to be direct caregivers
(Grady, 1991; McEvoy, Cannon, & MacDermott, 1991) and coordinators of care
(Hazelton, 1991; McEvoy et al.), as well as educators and patient advocates (Bujorian,
1988; Grady; McEvoy et al.; Rosse & Krebs, 1999). As research nurses, they are
expected to be facilitators, liaisons, (Engelking, 1992), and data collectors (Cassidy &
MacFarlane, 1991 ;Grady).
Ocker and Plank (2000) reviewed the nursing literature, analyzed job descriptions
of oncology nurses, and conversed with research staff, oncology staff, and a clinical nurse
specialist within an oncology research program in a large outpatient oncology clinic.
They identified three oncology nurse roles for involved with clinical trials: patient
educator, patient advocate, and study coordinator. Nurses greatly effect prospective
patients’ perceptions of clinical research. They explain technical and complex protocols
in understandable terms. As patient advocates, nurses have a critical role with the
informed consent process. They ensure that patients are treated with respect, dignity, and
as autonomous individuals (Barrett, 2002). Therefore, nurses are in an ideal position to
provide patients with information about informed consent, to facilitate physician-patient
communication and to serve as patient advocates (Winslow, 1984).
Berry, Dodd, Hinds, and Ferrell (1996) suggest that informed consent for
oncology clinical trials is an ongoing process involving many steps. Establishing and
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maintaining informed consent should be a multidisciplinary effort in cancer clinical trials.
As patient educators and advocates, nurses have maximized patient understanding and
minimized potential coercion.
The actual act of obtaining a signature on the consent form is the physician’s legal
responsibility, but nurses have a moral responsibility to ensure that patients have a good
understanding of that to which they are consenting (Rosse & Krebs, 1999). To be
effective in this role, nurses must be knowledgeable about fundamental concepts
associated with informed consent (Rosse & Krebs, 1999). As noted above in the study of
Meropol et al. (2003), the differences in perceptions of adult patients and their physicians
regarding treatment outcome expectations may be due to suboptimal patient-physician
communication discussions of clinical trial participation. Nurses can play a key role in
assessing and minimizing this discrepancy.
Nurse-Patient Relationships
Husted and Husted (2001) wrote extensively about the nurse-patient relationship
and stress the nurse-patient agreement. They developed a theory called Symphonology
which states; “Every human relationship arises from an explicit or implicit
agreement….The principles by which a professional makes a decision ought to be
derived from the actual dynamics of this agreement” (p. 9). The nurse is the “agent of a
patient doing for a patient what he would do for himself if he were able” (Husted &
Husted, 2001, p. 36). Husted and Husted (2001) prefer the term “agency” to “advocacy.”
They define agency, “the power or capacity of an agent to initiate action” (Husted &
Husted, 2001, p.285). A person’s agency is “the power to act on autonomous desires that
spring from his or her own reasoning” (Husted & Husted, 2001, p. 195). Part of a nurse’s
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role is to be an agent for his/her patient. The nurse agreed to protect the rights of the
patient through the implicit agreement between them. This implicit agreement forms the
basis of the oncology nurses’ role in discussing clinical trials with patients. As explained
in section D, the role of the oncology nurse consists of educator, consultant, and patient
advocate, or agent as Husted and Husted (2001) posit. The oncology nursing role as
educator and agent of clinical trials patients are all part of the nurse-patient relationship.
The nurse-patient relationship comprises the foundation for communication between
nurse and patient. During the communication process, as agents for their patients, nurses
provide clarification of information that a patient may not understand. This is especially
important with regard to informed consent required for oncology patients and clinical
trial participation. The nurse-patient relationship as stated by Husted and Husted enable
oncology nurses to help patients become more effective partners in the clinical trial
decision-making process.
E. Summary of the Review of Literature
The role of beliefs, attitudes and perceptions in the decision-making process and
in predicting behavior forms the foundation for this study. The TRA proposes that
attitudes guide behavior. It is a theoretical framework that was used in other nursing
studies evaluating attitudes and perceptions. Additionally, if behavior were expected to
be based on specific beliefs and attitudes, then measuring those beliefs and attitudes is a
way of predicting behavior (Sanbonmatsu & Fazio, 1990).
One way to begin to assess the actions of the oncology nurse towards patients
contemplating or participating in clinical research is to investigate their attitudes and
perceptions. Hence, the nurse’s perceptions and consequent attitudes regarding cancer
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clinical trials may ultimately dictate their behavior towards patients enrolled in or
contemplating enrollment into a cancer clinical trial. Within the practice of oncology
nursing, these behaviors can include direct patient care, coordination of care, patient
education, and patient advocacy.
Oncology nurses have a pivotal role when caring for patients considering
participation in a clinical trial. Nurses provide education to patients and clarify
information. This fact is underscored by the study by Aaronson et al. (1996). They
utilized a nursing intervention which demonstrated a positive effect on cancer patients’
awareness of the most important issues surrounding clinical trials participation.
Additionally, nurses serve as patient educators and assist patients in the decisionmaking process. Nurses perceive their role differently from that of other healthcare
professionals in that, they concentrate on patient advocacy and caring (Krisjansdottir,
1992). This caring focus enables nurses to ensure adequate communication with patients
about treatment regimens. Nurses may be more aware of patients’ attitudes towards
research due to this type of patient-nurse relationship. Nurses’ attitudes and perceptions
may influence patient’s opinions regarding participation and may reflect patients
concerns in this area. The nursing role and caring focus outlined above are all part of the
nurse-patient relationship. Within the nurse-patient relationship, specific to oncology
nursing, the nurse’s role consists of educator, counselor, patient advocate, direct
caregiver and investigator. Exploring oncology nurses’ attitudes and perceptions toward
clinical trials may help to predict the behaviors required to function optimally in these
roles.
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Studies show that patients often do not understand the purpose of clinical trials
and may have unrealistic expectations regarding their benefits (Cassileth, Lusk, Miller, &
Hurwitz, 1982; Daugherty et al, 1995). Nurses have an integral role in the informed
consent process. Further exploration of oncology nurses attitudes toward clinical trials
and their perceptions of patient understanding is needed.
The oncology nurse has an important role in all aspects of clinical trials and the
care of patients enrolled or contemplating enrollment. However, it is unfortunate that
there is very little information concerning nurses’ attitudes and perceptions regarding
cancer clinical trials. Only one study concerning oncology nurses’ attitudes towards
cancer clinical trials in a comprehensive cancer center exists (Burnett et al., 2001). These
data revealed that the majority of nurses feel that cancer clinical trials advance standards
of cancer treatment. However, approximately half would recommend their patients for a
clinical trial, most would not participate in a clinical trial if they had cancer. There
appears to be a discrepancy between what these oncology nurses feel about clinical trials
and what they would actually do. The authors’ recommendations for future research were
the to replicate their study with other comprehensive cancer center nurses; to conduct a
study with nurses from settings other than a comprehensive cancer center, and to compare
the findings between these different groups, and to study current nursing educational
methods and models of nurse-physician interaction in research settings. This study is an
attempt to examine the attitudes and perceptions of a more heterogeneous group of
oncology nurses.

CHAPTER III: METHODS
The chapter explains the study design. Followed by a description of the sample,
including sample size and the setting in which the data were collected. The information
about the instruments used is in the next section. Finally, procedures for data collection,
the protection of human subjects and the data analysis plan are the last three sections.
A. Design
This study was a descriptive, nonexperimental study of a sample of practicing
oncology nurses that explored oncology nurses’ attitudes and perceptions toward clinical
trial participation. The study further sought to understand factors that oncology nurses
believe influence patients’ decisions to participate in cancer clinical trials, and to learn
which nurses’ characteristics are predictive of positive attitudes towards cancer clinical
trials and perception of patient understanding.
A survey method was employed. The purpose of a survey design is to generalize
from a sample to a population, so inferences can be made about some characteristic,
attitude, or behavior of this population (Babbie, 1990). As noted in the review of the
literature, little is known about nurses’ attitudes and perceptions towards cancer clinical
trials. Most literature evaluating attitudes and perceptions towards clinical trials has
concentrated on patients, the community, and physicians, rather than on nurses. The
investigator used mailed survey instruments. There are a number of advantages of mailed
surveys. They allow for wide geographic coverage as compared with surveys
administered in person. Another advantage of a mailed survey is
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in the timing of the data collection. The assumption with a mailed survey is all the
members of the sample receive it nearly simultaneously. Therefore, the potential
influence on respondents’ experiences, opinions, or attitudes that might come from events
outside of or unrelated to the study is reduced and can be assumed to be equal for all
recipients of the questionnaire (Bourque & Fielder, 2003).
One of the greatest and most studied disadvantages of using mailed surveys is
their low response rate (Bourque & Fielder, 2003). According to Krosnick (1999), the
common thought when conducting a survey is to strive for a 70% response rate. He noted
response rates on national surveys have fallen in the last four decades. Krosnick
challenged the thought that high response rates correlate with a high degree of
representativeness of the sample and cited results in relation to national studies of voters.
When probability sampling was done, there was no longer a need to associate low
response rates with low representativeness (Krosnick, 1999). Research shows that a
second mailing approximately three weeks after the first mailing is more effective than
any other technique for increasing response (Dillman, 2000; Schaefer & Dillman, 1998).
Response rates reported from past mailed surveys sent to Oncology Nursing
Society (ONS) members ranged as follows: 23% (Jerewski, Brown, Wu, Meeker, Feng,
& Bu, 2005); 24% (Taylor, Highfield, & Amenta, 1994); 25% (Volker, 2001); 26%
(Rutledge & Engelking, 1994); 30% (Bavier, 2003); and 37.7% (Sarna, Wewers, Brown,
Lillington, & Brecht, 2001). The study by Jerewski, et al. (2005) used a stratified, random
sampling approach and asked questions regarding knowledge, attitudes, and experiences
about advanced directives analyzed with descriptive statistics and regression analysis.
Taylor et al.’s (1994) study also used a stratified random sampling approach asking
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questions about spiritual care analyzed using content analysis and descriptive statistics.
Volker (2001) used a sequential mailing technique to gather stories of nurses in relation
to requests for assisted dying. Rutledge and Engelking (1994) conducted a survey of
randomly selected oncology nurses to describe their experiences with cancer related
diarrhea, including occurrence and management. Bavier (2003) used a stratified random
sampling approach in describing types of disclosure discussions between oncology nurses
and patients/family members. Sarna et al. (2001) conducted a survey of randomly
selected members of ONS about tobacco control and barriers and facilitators to delivering
tobacco cessation interventions to patients. The authors do not state specific strategies
used to maximize response to their surveys. Sarna et al. (2003) stated that a reminder
postcard was sent to encourage return of the questionnaire but, when the postcard was
sent was not reported. However, three to four weeks after the first mailing (N = 5,000),
Rutledge and Engelking (1994) mailed another survey packet to nonrespondents. A total
of 1,288 nurses (26%) responded, 600 to the first survey and 688 to the follow-up. It is
encouraging to note that upon follow-up mailing Rutledge and Engelking (1994) yielded
a greater number of respondents compared to the first mailing. This study planned on
utilizing the same technique as Rutledge and Engelking (1994) to send a follow-up
mailing to nonrespondents in case the minimum sample size was not obtained with the
first mailing; however, a second mailing was not necessary (see Sample Size and
Procedures for Data Collection sections).
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B. Sample and Settings
In this study, a proportional stratified random sample of the membership of the
ONS was used to make inferences between oncology nurses characteristics and their
attitudes towards cancer clinical trials, their perception of patients’ knowledge of the
treatment plan and information needed related to clinical trials. In a proportional,
stratified random sample, the population is separated into groups based on their
proportions represented in the general population. Then, a random selection is drawn
from each group with the proportion from each stratum being the same as the overall
population. The stratified random sampling technique is an attempt at sharpening the
representativeness of the final sample (Polit & Beck, 2004).
Sample Size
To assess instrument and subscales validity, the investigator performed a factor
analysis of the data prior to the primary analysis evaluating the research questions (this
will be explained fully in the data analysis section of this chapter). Factor analysis
requires a minimum number of subjects per item for the instrument being utilized.
Gorush (1983) and Hatcher (1994) recommend a minimum subject per item ratio of at
least 5:1. The consensus among three authors is (Gorush, 1983; Hathcer, 1994; Nunnally
& Bernstein, 1994) the number of subjects per item should be 5:1 to 10:1. Other authors
have reported that there may not be one ratio that will work in all cases and a rule of
thumb is an N>100 and that most factor analytic studies use N>200 (MacCallum,
Widaman, Preacher, & Hong, 2001).
For this study the investigator utilized a 26-item instrument (see appendix A and
instrument section of this Chapter) and the investigator followed a 5:1 to 10:1 ratio of
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subjects per item; therefore, the minimum number of subjects needed for this study
was130. However, after consulting a statistician with over 20 years experience in
designing surveys, it was decided that a sample size of 230 subjects would be better (B.
Pearman, personal communication, April 24, 2006). It has been shown that larger
samples (i.e., >200 subjects) are better than smaller samples, because larger samples tend
to minimize the probability of errors, maximize the accuracy of population estimates, and
increase the generalizability of the results (B. Pearman, personal communication, April
24, 2006; Gorush, 1983; MacCallum et al., 2001).
Sample
A sample of registered nurse (RN) members of ONS who reside in the United
States (US) and permit ONS to release their addresses was utilized. The total ONS nurse
and non-nurse membership is approximately 32,000, approximately 23,000 members
allow their names to be sold to outside organizations (ONS, 2006). There are
approximately 16,150 nurse members who self-report their primary functional area as
patient care or research with adults, excluding nurses who self-report their primary
position as researcher/principal investigator.
One thousand labels of names and addresses were purchased from ONS for nurses
who reside in the U S and who self-report patient care or research with adults as their
primary functional area, and are employed full, or part-time, . The investigator requested
that the list excludes nurses who reported that their primary position as
researcher/principal investigator. There may be nurses who identify their primary
functional area as “research” but in fact are clinical trials nurses and the investigator
wanted to include them. Additionally, the investigator was interested in exploring the
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attitudes and perceptions from oncology nurses who have direct patient care and whose
primary position includes, but is not limited to, staff nurse, clinical nurse specialist, nurse
practitioner, clinical trials nurse, and patient educator. This sample represents the
majority of the population of nurses who care for oncology patients and is an attempt to
improve the generalizability of the study.
The investigator requested ONS to stratify the 1,000 names by two variables: 1)
primary work setting (e.g., in-patient hospital unit, outpatient facility or clinic, public
health or visiting nurse service, hospice, etc.); and 2) highest degree attained (e.g.,
diploma, associate’s, bachelor’s, masters, doctorate). A random sample within each
category was selected in proportion to the size of the group in that category. This group
was a representative sample of the study population with the above proportional
categories. The study packet was mailed to all 1,000 selected members. A cover letter
(see Appendix B) was included in the mailing. This over sampling was required due to
previously reported response rates between 24-37% to ONS mailed surveys.
C. Instruments
The nurses were asked to complete two instruments, the modified Nurses’
Attitude Survey (NAS) (Appendix A), and a Demographic Information Form (see
Appendix C).
Nurses Attitude Survey
The original NAS was survey tool developed by Meropol and colleagues (Burnett
et al., 2001) that addresses nurses’ attitudes toward cancer clinical trials and their
perceptions about patients’ reasons for participating as research subjects. The instrument
was used only once at Roswell Park Cancer Institute (RPCI). RPCI is a freestanding
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National Cancer Institute (NCI)-designated comprehensive cancer center. Between
October 1996 and February 1997, 417 RNs employed at RPCI were surveyed. Nurses at
RPCI care for a wide variety of patients in a array of settings, including outpatient and
inpatient units, intensive care units (ICUs)/bone marrow transplant (BMT) units, and
clinical research services. Two hundred-fifty (60%) of the 417 nurses responded. Ninety
percent of the sample was female; 88% was white; the mean age of subjects was 42
years; and 47% of subjects were educated at the bachelor’s or master’s level. Practice
setting was distributed fairly evenly across inpatient facilities, outpatient clinics, and
ICUs and BMT units. Twenty-seven (11%) subjects identified themselves specifically as
research nurses. Approximately one third of the total respondents (n = 82) reported caring
for at least 50 patients annually on clinical trials.
The original NAS consists of a total of 59 consecutively numbered items
including demographic information questions. The tool is divided into four sections:
Section 1 (Clinical Research Using Patients as Research Subjects) consists of 15 items
plus space for comments; Section 2 (Patient Care and Patient Communication) consists of
11 items and a space for comments; Section 3 (Nurses’ Role in a Cancer Institute) is
comprised of 16 items plus space for comments. To answer items in Sections 1 through 3,
the participant chooses responses from a 5-point Likert scale (1 = strongly disagree, 2 =
somewhat disagree, 3 = neither, 4 = somewhat agree, and 5 = strongly agree). Section 4
(About You) consists of 17 demographic questions.
Modification of the NAS. With permission from the authors (see Appendix D), the
investigator modified the instrument for this study. This modification was requested
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because certain items from the original instrument would obtain information that was
outside the purpose of this study and only germane to the original study.
The 15 items contained in Section 3 were statements that address issues related to
the nurses’ employment, such as job satisfaction and support at work. Section 3 was
deleted, because the information is outside the scope of this research. All demographic
questions were included on a separate form (see Appendix C). Sections 1 and 2 of the
NAS were modified and consisted of the 26 consecutively numbered items included in
the original instrument (see Table 1).
Table 1
Modification of NAS
________________________________________________________________________
NAS section
Original NAS items
Modified NAS items
1. Clinical research using patients
as research subjects

1–15

1–15

2. Patient care and patient communication

16–26

16–26

3. Nurses’ role in a cancer institute

27–42

Deleted

4. About you

43–59

Demographic
information
to be captured on
a separate form
________________________________________________________________________
Within the original instrument, the authors derived two subscales consisting of six

items each. The authors used subscale one (Items 1, 5, 6 7, 8 and 11) to report nurses’
attitudes toward patient participation in clinical trials and, subscale two (Items 12, 13, 18,
20, and 21) to report nurses’ perceptions about factors related to patient care issues (e.g.,
respect, understanding of the treatment regimen, and informational needs). Cronbach’s
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alphas were reported for the two subscales as 0.78 and 0.63, respectively (Burnett et al.,
2001). A Cronbach’s alpha of 0.63 is lower than the widely-accepted social science
minimum of 0.70. Usually an alpha level 0.70 and above is acceptable; however, it is a
common misconception that if the alpha is low, it must be a poor test. Actually, the test
may measure several attributes or dimensions rather than one and, thus, the Cronbach’s
alpha is deflated (Santos, 1999).
The authors of the NAS analyzed their data using the two subscales as outlined.
Upon review of the instrument, the investigator found other items that could be grouped
together to answer the research questions of this study and utilize all items in Sections 1
and 2 (see Table 2). However, the grouping of items in table 2 was proposed before the
factor analysis was executed. After the factor analysis, the investigator found that some
of the proposed items grouped with each other, while others did not (see chapter 4,
Results). The authors of the NAS report that they established face and content validity for
the instrument by an extensive review of the literature and a review of the instrument by
three medical oncologists and two oncology nurses (Burnett, et al., 2001). Therefore, it
was prudent that the investigator psychometrically evaluate construct validity of the
modified NAS to assess that the dimensions (attitudes and perceptions) are being
measured by the instrument subscales (Waltz, Strickland, & Lenz, 1991). Factor analysis
was employed to justify these dimensions (see Psychometric analysis section chapter 4).
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Table 2
Modification of the NAS Subscales to Match Research Questions
_______________________________________________________________________
Research questions
Modified NAS subscale items
Original NAS
subscale items
_______________________________________________________________________

1. What are oncology
nurses’ attitudes toward
the benefits of cancer
clinical trials?

5. Clinical research improves
patient care for the patient
involved.
6. Hospitals that conduct clinical
research have better standards of
care than hospitals that do not.
7. Clinical research in oncology is
important in improving standards
of care in oncology.
8. Patients should be encouraged
to participate in research.
11. If I had cancer, I would prefer
to be treated as part of a clinical
trial.

1, 5, 6, 7,
8, & 11

2. What are nurses
attitudes about how
effective a research drug
or experimental therapy
should be shown to be
before it is offered to
patients?

15. In your opinion, in order for a
research drug or experimental
therapy to be offered to patients, it
should have at least a _____%
chance of producing a desired
effect (please insert a number)

Reported as frequency
and distribution table
by original authors

3. What are the nurses’
perceptions regarding
patients’ understanding of
clinical trials and
treatment regimen

12. In general, patients are well
informed when they choose to
participate in a clinical trial.
13. Patients are often unaware that
their treatment is part of a research
protocol.
16. Patients’ wishes regarding
treatment are respected by nurses
19. Patients understand their
prognosis and therapy goals.
20. Patients’ prognoses are usually
well explained.
21. Patients want to be informed.

12, 13, 18, 19, 20, &
21.
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Table 2 (continued)
Reported as a
frequency distribution
table by original
authors

4. What factors do nurses
perceive to influence a
patient’s decision to
participate in a cancer
clinical trial?

14. Patients participate in research
because:
A. Wish for cure
B. Wish for improved quality
of life (i.e., symptom
control)
C. Hope for better medical
care
D. Desire to please their
oncologist
E. Pressure from oncologist
F. Wish to help others
G. No other option
H. Family wishes
I. Inability to accept that
nothing else can be done
J. Inability to accept
death

5. What are nurses’
perceptions of patients’
decision-making processes
and the desire for
information regarding
clinical trial participation?

22. When being told about their
therapy, most patients pay more
attention to potential benefits of
therapy than side effects.
23. Most patients are willing to
accept side effects for even a small
benefit if therapy.
24. Patients are often frightened to
ask questions.
25. Patients’ decisions whether to
accept or not accept toxic
chemotherapy is
strongly influenced by their family
preferences.

N/A

6. What are the
perceptions of nurses
regarding where clinical
research should be
conducted and the role of
oncologists and nurses in
clinical trials?

1. Conducting research is an
important role of oncologists.
2. Clinical research should be
conducted only in cancer
centers/institutes.
3. It is appropriate for oncologists
to invite their clinic patients to be
subjects in trials that they conduct.

N/A
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Table 2 (continued)

4. It is appropriate for oncologists
to be the person consenting
research subjects for their trials, if
the research subjects are their own
clinic patients
9. Oncologists put too much
pressure on patients to participate
in clinical trials
10. Nurses put too much pressure
on patients to participate in clinical
trials
17. Patients’ wishes regarding
treatment are respected by
oncologists
18. Patients understand their plan
of care/treatment.
26. Oncologists believe that
patients are willing to accept side
effects for even a small benefit of
therapy.
7. Do the demographic
Were analyzed by regression
Predictors reported by
variables of age, education equations based upon the
original authors.
level, number of years in
responses to the above items.
oncology, position of
oncology nurses, and
practice setting serve as
significant predictors to
attitudes and perceptions?
________________________________________________________________________
Eight practicing masters prepared oncology nurses completed the modified
instrument, as part of a field test of the instrument package and to provide feedback on
the items. These nurses were not part of the primary study. Each nurse took fewer than10
minutes to complete the instrument. They all felt that the instrument asked for their
opinion regarding cancer clinical trials, including information specifically about patients
who participate in these trials. In the unmodified instrument Item 1 states “Conducting
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patient research is an important role of oncologists” and Item 9 states “Doctors put too
much pressure on patients to participate in clinical trials.” The nurses recommended
using similar language throughout the instrument. Therefore, wherever an item addressed
doctor it was changed to “oncologist.”
Demographic Information Form
The Demographic Information Form (DIF) was designed by the investigator using
some of the demographic items contained on the original NAS and on the 2006 ONS
membership application/renewal form. The DIF contained 10 items; six items were from
a list of choices and four responses were open-ended requiring subjects to fill in a blank.
One purpose of the DIF was to assist with the analysis of the sample characteristics in
relation to the overall membership of ONS. Questions one, three, four, seven, nine, and
10 from the DIF were used in the evaluation of research question number seven that
explored demographic variables (age, highest education level, whether or not the nurse
actually works with patients contemplating enrollment or currently enrolled in a clinical
trial, number of years in oncology, primary work setting, and primary position of
oncology nurses ) and evaluated if they served as significant predictors related research
questions one through six (see Table 3). The remaining four questions on the DIF were
used to further describe the sample (gender, current certification in oncology nursing,
number of years as an RN, and percentage of patients offered cancer clinical trials where
the subject worked). The questions were based on the independent variables of interest
(see Table 3) and some mirror the items on the ONS membership application.
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Table 3
Independent Variables from DIF
_______________________________________________________________________
Independent variables (demographic categories) addressed
DIF question
in research question 7
_______________________________________________________________________
Age

1

Highest education.

3

Working with patients contemplating enrollment or
enrolled in clinical trials.

4

Number of years in cancer nursing.

7

Primary work setting.

9

Primary position.
10
________________________________________________________________________
D. Procedures for Data Collection
The investigator obtained three duplicate sets of mailing labels from ONS, for a
total sample of 1,000 members. This over-sampling was used with the goal of a 20-25%
response rate in an attempt to yield 230 usable responses. All 1,000 names from the first
set were mailed the study packet. The only identification was a numeric code on the
return envelopes and corresponding numerical codes on the second and third mailing
labels. When a subject returned the survey, his/her name was removed from the second
and third sets of mailing labels and the envelopes shredded. The code did not appear on
any of the instruments or cover letter. This was to ensure that names were not connected
with answers in any way and to provide anonymity to the respondents. If there were
fewer than 230 usable surveys 3 weeks after the first mailing, the investigator planned on
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mailing a second survey packet with the instruments and a new cover letter (Appendix E)
to all remaining names (Dillman, 2000). This was not necessary, because the investigator
had received more than 230 usable surveys 3 weeks after the mailing (see chapter 4,
Results). At the end of the study, the investigator destroyed all codes and remaining
address labels.
Additionally, the cover letter (see Appendix B) stated the inclusion criteria for
this study as follows: (a) nurses whose primary functional area is patient care or research
with adult patients, and (b) any primary position other than researcher/principal
investigator. There was a box on the cover letter for the subject to check if they do not
meet these criteria with instructions to return the cover letter in the supplied stamped
addressed envelope.
After obtaining approval from the Institutional Review Board (IRB) of Duquesne
University, survey packets were mailed (Appendix F). The packets contained: (a) an IRB
approved cover letter (Appendix B), (b) the modified NAS (Appendix A), (c) the DIF
(Appendix C), (d) and a stamped return envelope addressed to the investigator.
E. Procedures for the Protection of Human Subjects
The investigator requested approval for conducting the study from the
IRB of Duquesne University, utilizing standard forms and procedures set forth by the
committee. The investigator provided an overview of the research questions, design,
methods, and a sample packet of data collection tools. The IRB approved the study on
May 24, 2006. The investigator received a letter from the chair of the Duquesne
University IRB, Dr. Paul Richer (Appendix F) stating that the study received expedited
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approval as well as an IRB approved cover letter to be used in the survey packet (see
Appendix B).
Participation in the proposed study was voluntary, and all subjects had the right to
refuse. Potential subjects were informed that results would be reported in an aggregated
format, with no information identifying any individual. The only identification was a
numeric code on the return envelopes and a corresponding numerical code on the second
and third set of mailing labels. As mentioned above, when a subject returned a survey the
person’s name was removed from the mailing list and the envelopes shredded. The code
did not appear on any of the instruments or cover letter. At the end of the study, all codes
and remaining address labels were destroyed by the investigator.
During the study the investigator, kept all of the returned instruments and address
labels in a locked file cabinet separate from any data. The completion of the survey
instrument and the mailing of the instrument to the investigator were considered to be
consent by the individual to participate in the proposed study. The cover letter provided a
means for individuals who had concerns about the study and wished to discuss issues a
way to contact the investigator (Appendix B).
F. Data Analysis Plan
Data analysis occurred in two steps. In step one, the investigator psychometrically
evaluated the survey instrument by completing a factor analysis of the data to confirm the
validity of the grouped items with this population of oncology nurses and assessed
reliability of the instrument and the subscales. Data were analyzed statistically using
SPSS® (version 11.5) (SPSS Inc., Chicago, IL).
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Upon receipt of each completed survey, a research assistant entered the data onto
a spreadsheet (Excel by Microsoft®, Redmond, WA) created by the study statistician. For
quality control the investigator rechecked all data entered for each subject. The data were
then exported to SPSS® for data analysis.
As noted in the review of the literature in chapter 2, the NAS was used in one
pilot study of oncology nurses in a comprehensive cancer center (Burnett et al., 2001),
and the investigator could not find any other instruments that have been created to
measure nurses’ attitudes and perceptions regarding cancer clinical trials. As stated, the
authors of the original instrument analyzed data using two subscales consisting of six
items each, which are embedded within the entire NAS. The authors used Subscale 1 to
measure nurses’ attitudes toward patient participation in clinical trials, and Subscale 2 to
measure nurses’ perceptions about factors related to patient care issues (e.g., respect,
understanding of the treatment regimen, and informational needs). In addition to the 12
grouped items which make up Subscale 1 and 2 (six items for each subscale), the
remaining items on the NAS were grouped together to address the research questions for
this study. Therefore, all of the research questions were evaluated by four subscales and
two individual items, which contained all the 26 items of the NAS. This will be explained
fully in the analysis of variables section of this chapter.
In establishing six groupings of items to address six research questions, validity
and reliability of the NAS was evaluated prior to addressing the research questions posed
by this study. Psychometric evaluation of the NAS was accomplished by factor and
reliability analysis. Factor analysis addresses the validity of a scale or subscale by
evaluating the extent to which the abstract constructs purported to be measured, can be
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inferred from the factors or subscales (Waltz et al., 1991). Reliability measures the
internal consistency and reliability of a scale or subscale and was evaluated by
calculating Cronbach’s alpha (Polit & Beck, 2004).
Factor Analysis
Factor analysis of the NAS was performed first to determine if the proposed items
and subscale items grouped together. Factor analysis is a generic term for a family of
statistical techniques concerned with the reduction of a set of observable variables in
terms of a small number of latent factors or constructs (Hutcheson & Sofroniou, 1999).
Factor analysis was developed primarily for analyzing relationships among measurable
entities, such as survey items or test scores (Gorsuch, 1983). The underlying assumption
is there exists a number of unobserved latent variables (or “factors”) accounting for the
correlations among observed variables, such that if the latent variables are partialled out
or held constant, the partial correlations among observed variables all become zero
(Morrison, 1990). In other words, the latent factors determine the values of the observed
variables. The main applications of factor analytic techniques are (a) to reduce the
number of variables and (b) to detect structure in the relationships between variables that
classify similar variables together (Hutcheson & Sofroniou, 1999).
The factors, then, are groups of variables measuring a common construct or
factor. In a principal components factor analysis, all sources of variability (unique,
shared, and error) are analyzed for each variable. In factor analysis, only shared
variability is analyzed (Gorsuch, 1983). This is based on the assumption error and unique
variance which only serve to confuse the underlying structure of the variables. In this
study, a principal components factor analysis was utilized. This study also utilized an
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orthogonal or varimax rotation (Gorsuch, 1983). This rotation results in identifying
factors that are uncorrelated with each other. The factor loadings or the matrix of
correlations between all observed variables and factors was inspected, since the size of
the loading is indicative of the relationship between each observed factor and variable.
The interpretation of factors or analysis always involves a certain amount of subjectivity.
In order to be effective and avoid potential bias, the minimum factor loading was set at
0.30 (Gorsuch, 1983; Waltz & Bausell, 1981). Items or variables loading below 0.29
were considered for elimination from the scale. It also was anticipated that items would
load on one, and only one, factor (Gorsuch, 1983). This was accomplished before any
further analyses of data, so that the grouped items could be evaluated and altered if
necessary.
It was anticipated that most of the proposed subscale items would factor together
(Betsy Pearman, personal communication, April 24, 2006). However, the factor analysis
revealed that some of the proposed item groupings (Table 2) factored together, while
some items factored with others. The investigator planned on two strategies to address
factor loading of an item or items below 0.30: (a) If new factor arrangements (subscales)
were identified and provided useful information and evaluated the underlying constructs
(attitudes and perceptions), then the investigator would utilize the new arranged factors to
analyze the data; (b) if the constructs were not identified within a new factored
arrangement then the investigator would evaluate reliability of the new factored
arraignment and compare it to the reliability of the proposed subscales. The more reliable
arrangement would then be used for the data analysis. The investigator found that some
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items of the proposed subscales (Table 2) factored together, while other items factored in
with different items (See chapter 4, Psychometric analysis section).
Reliability
Reliability of the NAS and the subscales of grouped items were measured with a
Cronbach’s alpha. Cronbach’s alpha is a coefficient of reliability (or consistency) and is
the most common estimate of internal consistency of items in a scale (Cronbach, 1951).
Cronbach’s alpha measures how consistently a set of items is measured. In other words,
upon repeated testing of a scale or subscale, the same results are obtained, and to what
extent the item responses obtained at the same time correlate with each other (DeVellis,
2003). Three factors that can affect the size of an alpha coefficient include the number if
items on the subscale, the ability of the person completing the items, and the method of
computing reliability (Polit & Beck, 2004).
Analysis of Research Questions
Research Questions 1, 2, 3, 5, and 6 were analyzed by evaluating the mean scores
obtained from the survey items (summed subscale scores for Questions 1, 3, 5, and 6 and
mean percent for question 2) with p = 0.05 as the level of significance (see chapter 4 for
results). Research Question 4 was analyzed using descriptive statistics and frequencies of
Item 14 were reported.
Stepwise multiple regression was used to analyze research Question 7. For this
analysis, regression was used to test the effects of six independent (predictor) variables
(age, education level, number of years in oncology, whether nurses care for clinical trial
patients or not, position of oncology nurses, and practice setting) on the dependent
(criterion) variables, attitudes and perception, as measured by the NAS subscales.
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Regression analysis measures the degree of influence of the independent variables on the
dependent variables (Stevens, 2002). Multiple regression can establish that a set of
independent variables explains a proportion of the variance in a dependent variable at a
significant level (through a significance test of R2), and can establish the relative
predictive importance of the independent variables (Brace, Kemp, & Snelgar, 2006). The
adjusted R2 takes into account the number of variables in the model and the number of
participants on which the model was based. The adjusted R2 value gives the most useful
measure of the success of the model. However, there may be very little difference
between the R2 and adjusted R2, and some authors recommend checking for differences
between the two and reporting only the R2 (Brace et al.; Stevens, 2002,). An R2 close to
1.0 indicates that almost all the variability with the variables specified in the model have
been identified. Therefore, a R2 close to 1.0 is desirable because it indicates that the
predictor variables are a good predictor of the criterion (dependent variables).
Conversely, a low R2 indicates the predictor variables account for little variance and there
is variance in the model that is accounted for from an unknown source. When a
regression model has a low R² there may be some other factor accounting for the
variance. As an example, if the R² is 0.12, then only 12% of the variance is accounted for,
and there is an unknown variable that will affect future results, if that regression model
were being used to predict group scores on a subscale. It would be difficult to use the
predictor variables to predict the scores on the subscale if the regression model is only
accounting for 12% of the variance (Tabachnick & Fidell, 2001).
Another important result from a multiple regression analysis is the standardized
regression coefficient, beta (ß). The beta regression coefficient is a measure of how
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strongly each predicator variable influences the dependent or criterion variable. The
higher the beta value, the greater the impact of the predictor variable on the dependent
variable (Brace, et al., 2006). Five stepwise multiple regression models were constructed
to explore further the relationship of the independent variables and the outcome variables
of attitudes and perceptions.
As a general data analysis approach, bivariate comparisons of mean scores were
performed using one-way analysis of variance (ANOVA) tests with age, educational
level, whether the nurse works with a patient enrolled on or contemplating enrollment in
a clinical trial, years in cancer nursing, primary work setting, and primary position as
independent variables and the scores of the subscales as the dependent variables. When
significant differences in mean scores were found within an independent variable a posthoc multiple comparison test then was performed.
For independent variables where there were more than two groups, the data were
further analyzed with a Bonferroni post-hoc multiple comparison test. The Bonferroni
adjustment is a statistical adjustment for multiple comparisons (Seaman, Levin, & Serlin,
1991). The Bonferroni post-hoc test uses t tests to perform pairwise comparisons between
group means, but controls overall error rate by setting the error rate for each test to the
level of significance (alpha level) divided by the total number of tests (Keppel &
Wickens, 2002). Hence, the observed significance level is adjusted for the fact that
multiple comparisons are done.
The Bonferroni post-hoc test calculates an adjustment as a way of control when
multiple tests of the data are analyzed, and accounts for testing the same population many
times (Keppel & Wickens, 2002). For example, if five groups are being tested in a
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pairwise fashion, there are10 possible combinations of pairwise comparisons. The alpha
level of significance for this study was set at p = 0.05. With the Bonferroni adjustment
the alpha level is divided by the number of pairwise comparisons. For 10 pairwise
comparisons, the level of significance now becomes p = 0.005. This ensures that the
overall chance of making a Type I error is still less than 0.05.
Independent Variable Groupings
Age. The independent variables were placed into groups for data analysis. The
sample was divided into two groups to evaluate age: Group 1 represents nurses’ less than
or equal to 40 years old and Group 2 represents nurses greater than 40 years old. The cut
point of 40 years of age was chosen for several reasons. Burnett, et al. (2001), found age
greater than 40 years was a predictor of positive attitudes towards clinical research.
Additionally, the investigators found that 236 (78.4%) nurses were 40 years or older with
a mean age of 48. Both the sample and the ONS membership reflected the general
nursing population with the majority over the age of 40 (Buerhaus, 2002). Moreover,
66% of ONS members are over the age of 40 (Kristina Gantner, Personal
Communication, July 19, 2006).
Educational level. To evaluate the independent variable of educational level it
was classified into three different groups. Group 1 included nurses who had a diploma in
nursing or an associate degree in nursing or any other field. Group 2 included subjects
with a bachelor’s degree in nursing or any other field. The third group included subjects
with a master’s degree or higher in nursing or any other field. These groupings were
chosen to see if there were differences in the responses of subjects with bachelor’s
degrees compared to subjects with lower or higher educational degrees.
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Working with clinical trial patients. Question number four on the DIF asked
subjects if they work with, or care for, patients contemplating enrollment in, or currently
enrolled in, cancer clinical trials. The subjects responded either yes or no. For the data
analysis the subjects were divided into two groups, Group 0 = no and Group 1 = yes.
Number of years in cancer nursing. To evaluate for differences in responses, the
number of years a subject worked as an oncology nurse was divided into three groups.
Group 1 were subjects who indicated less than ten years experience, Group 2, 11–20
years experience, and Group 3 greater than 20 years experience. The investigator decided
upon three groups based upon the average number of years falling between 10–20 years.
He felt that a group with less experience and a group with more experience than the
average were warranted to provide meaningful comparisons.
Primary work setting. For primary work setting there were three main groups of
subjects, inpatient setting, outpatient setting, and other. These groups were further
separated into six different work settings. Group 1 consisted of bone marrow transplant
unit/intensive care unit (BMTU/ICU) nurses; Group 2 consisted of nurses working on a
medical surgical inpatient oncology unit and an inpatient oncology specialty unit
(MSOU). The Group 3 consisted of nurses who stated they work at a hospital based
infusion center (HBIC). Group 4 consisted of nurses who reported they work in a
physicians’ office (MDO); Group 5 reported they work in a corporate or industry setting
(CI), and Group 6 were nurses who reported “other” (OTHER). These groups represent
the majority of nurses working in oncology and in the ONS membership (Kristina
Gantner, personal communication, July 19, 2006).
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The investigator decided to include Group 5, corporate/industry practice setting,
in the data analysis for several reasons. This variable is identical to a choice on the 2006
ONS membership application. The cover letter informed subjects that they were selected
to receive the survey based upon a random sample of nurses who self-report their primary
functional area as patient care or research with adults, excluding those who self report
researchers/principal investigators as their primary position (inclusion criteria). The cover
letter gave the subjects the opportunity to check a box and return the letter if they did not
meet these inclusion criteria. Lastly, it was impossible to differentiate between nurses
who work in corporations and provide patient care, those who work in research
organizations providing clinical trial support, and those who work in the pharmaceutical
industry.
Primary position. The variable, primary position was divided into four groups for
the analysis. This information was taken from the responses to question 10 on the DIF,
which asked subjects to indicate their primary position. This question is identical to an
item on the ONS membership application, asking for the same information. Group 1
included nurses who indicated they were staff nurses; Group 2 included subjects who
indicated they were clinical nurse specialists or nurse practitioners (CNS/NP); Group 3
were subjects who reported they were clinical trials nurses (CTN), and Group 4 were
subjects who indicated “other” primary position. The four primary positions represent the
majority of nurses included in the 2006 ONS membership (Kristina Gantner, personal
communication, July 19, 2006).

CHAPTER IV: RESULTS AND SUMMARY
A. Introduction
This study examined oncology nurses’ attitudes toward cancer clinical trials, and
identified nurses’ perceptions of the understanding that patients have about the clinical
trial process and the reasons for patient participation in clinical research. This study also
investigated factors which may influence oncology nurses’ attitudes and perceptions.
These factors include age, educational preparation, length of time in oncology nursing,
whether or not the nurse actually cares for patients contemplating enrollment or who are
currently enrolled in a clinical trial, primary position, and work setting. The investigator
believed that all of these factors could influence oncology nurses’ attitudes and
perceptions. Data were collected from the nurses’ answers to the items contained on the
modified Nursing Attitudes Survey (NAS) and Demographic Information Form (DIF).
This chapter includes the demographic characteristics of the oncology nurses
sampled, psychometric analysis of the modified NAS, the results of the analysis of the
research questions, and a summary.
B. Sample
This exploratory study obtained data from a national sample of oncology nurses
who were members of the Oncology Nursing Society (ONS). One thousand surveys were
mailed, and 357 nurses responded, giving a response rate of 35.7%. Fifty six respondents
(15.6%) returned the cover letter and marked the box that indicated they did not meet the
inclusion criteria for this study. Two surveys (0.5%) were returned by the U.S. postal
service, because the addresses were not valid. The final sample consisted of 301 subjects
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who completed the NAS and DIF; therefore, the actual response rate was 30.1%. Table 4
lists the demographic characteristics of the oncology nurses sampled.
Table 4
Demographic Characteristics of Sampled Oncology Nurses (N = 301)
Characteristic
Gender
Male
Female
Age (years)
20-39
≥ 40
No answer
Education level*
Diploma in nursing
Associate’s degree
Bachelor’s degree
Master’s degree
Doctoral degree
Certification
OCN®
AOCN®
AOCNP®
AOCNS®
Other

N

%

6
259

2
98

64
236
1

21.3
78.4
0.3

40
46
83
93
39

13.3
15.3
28
31
13

140
33
7
4
34

46.5
11
2.3
1.3
11

* Associate’s, bachelor’s, master’s and doctorate degrees totals combine nursing and other fields

Ninety eight percent (n = 259) of the subjects were female, and 2% (n = 6) were
male. The majority (n = 236, 78.4%) reported their age as 40 years old or greater. Thirtynine (13%) respondents reported that they had a doctoral degree in nursing or another
field as their highest education level. The majority of subjects (n = 93, 28%) had a
master’s degree in nursing or another field, followed by 28% (n = 83) of subjects who
reported that they had a bachelor’s degree (in nursing or another field) as their highest
education level. Almost one-half (n =140, 46.5%) were OCN® certified.
Demographic information regarding work setting and primary position was collected.
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Table 5 lists work setting and primary position of the nurses sampled.
Table 5
Work Setting and Primary Position
Work setting
In-patient
BMTU
ICU
Medical-surgical unit-general
Medical-surgical unit-oncology
Oncology specialty unit
Other
No answer
Outpatient
Home Care
Hospital based clinic/infusion center
Physician office
Radiation oncology-Hospital based
Other
No answer
Other
Corporate/industry
Extended care facility
HMO
School of nursing
Self employed
Other
No answer
Primary position
Staff nurse
Nurse educator
Nurse manager
Clinical nurse specialist
Clinical trials nurse
Academic educator
Nurse practitioner
Nurse researcher
Case manager
Other
No answer

N

%

14
2
1
54
25
20
3

4.7
0.7
0.3
17.9
8.3
6.6
1

3
55
46
11
25
3

1
18.3
15.3
3.7
8.3
1

26
1
3
6
6
12
3

8.6
0.3
1
2
2
4
1

116
8
17
35
17
4
45
8
7
41
3

38.5
2.7
5.6
11.6
5.6
1.3
15
2.7
2.3
13.6
1

76
There were two questions on the DIF that asked the subjects to report the number
of years as a RN and the number of years as a RN in cancer care. The mean number of
years that subjects reported they had RN experience and experience as a RN in cancer
care was 20.5 years and 13.23 years, respectively. The minimum number of years as a
RN that was reported was 1 year and the maximum was 51 years. For the variable years
as a RN in cancer care, the minimum number of years that was reported was 0 and the
maximum was 36 (see Table 6).
Table 6
Nurses’ Experience in Practice as a RN and a RN in Cancer Care

N=301
Mean
Median
Standard deviation
Range
Minimum
Maximum

Years as a RN
valid 301
missing 0
20.50
20.00
11.019
50
1
51

Years as a RN in cancer care
298
3
13.23
12.00
8.807
36
0
36

Nurses indicated “yes” or “no” to a question that asked if they worked with or
cared for patients contemplating enrollment or enrolled in clinical trials. More than two
thirds of subjects (n = 249) reported that they cared for patients contemplating enrollment
in or currently enrolled in clinical trials (see Table 7).
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Table 7
Nurses Caring for Clinical Trial Patients
Response
Yes
No
Total
Missing
Total

n
249
51
300
1
301

%
82.7
16.9
99.7
0.3
100

Despite this large percentage, the respondents reported that approximately a third
of patients (M =32.76%, SD=30.043) who they care for were offered cancer clinical trial
at the nurses’ place of employment. The minimum percent of patients offered any type of
clinical trial was 0% and the maximum was 100%. However, these data should be
interpreted with caution as 58 of the 301 subjects (19.2%) did not answer this question.
C. Psychometric Analysis of the Modified NAS
Factor analysis of the NAS was performed first to determine if the proposed items
subscale items grouped together. The underlying assumption of factor analysis is that
there exists a number of unobserved latent variables (or “factors”) accounting for the
correlations among observed variables, such that if the latent variables are partialled out
or held constant, the partial correlations among observed variables all become zero
(Morrison, 1990). In other words, the latent factors determine the values of the observed
variables. The main applications of factor analytic techniques are (a) to reduce the
number of variables and (b) to detect structure in the relationships between variables and
to classify the variables (Hutcheson & Sofroniou, 1999).
It was anticipated that most of the proposed subscale items would factor together.
However, the factor analysis revealed that only some of the proposed item groupings
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factored together, while some items factored with others. The investigator found that
some items of the proposed subscales factored together, while some other items factored
in with different items
Cronbach’s alpha for the entire modified NAS, excluding Items 14 and 15, was
0.72. Nunnally and Bernstein (1994) recommended that the alpha be between 0.70-0.90;
therefore 0.72 is acceptable, especially for a new instrument used in only two research
studies. These data support internal consistency for the total instrument. Any items
negatively correlated to the total were rescaled to maintain consistency of attitudinal
direction across items within each subscale and the total scale. There are certain
circumstances in which the “alpha of some items may be negative; therefore, the data
should be recoded if necessary to assure that all items are coded in the same conceptual
direction” (De Vellis, 2003, p. 92). Based on these results, the following items on the
modified NAS were recoded and the scoring reversed: 2, 9, 10, 13, 22, 23, 24, 25, and 26.
For example, the response of Strongly Agree was originally scored as a 5, Somewhat
Agree was scored as a 4, Neutral was scored as 3, Somewhat Disagree was scored as a 2,
and Strongly Disagree was scored as a 1. The new rescored items were as follows:
Strongly Agree = 1, Agree = 2, Neutral = 3, Disagree = 4 and Strongly Disagree = 5.
The construct evaluated by Item 14 was nurses’ perceptions of motivations for
patient participation in clinical research. Item 14 stated, “Patients participate in research
because of:” and 10 subitems (letters A-J) followed with corresponding evaluations using
a 5-point Likert scale. Item 14 was the single item to evaluate research Question 4: “What
factors do nurses believe influence a patient’s decision to participate in a cancer clinical
trial?” The Cronbach’s alpha for this item was 0.68. Furthermore, Item 15 asked the
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subjects for their opinion and instructed them to write a whole number for percent chance
that a research drug should have of producing a desired effect before being offered to
patients. Cronbach’s alpha coefficient reliability is not calculated on single numbers that
are not scaled responses (DeVellis, 2003). When items are used to form a scale (or, as in
this study, subscales) and the score from the individual item is combined into a single
numerical value, the items need to have internal consistency and to be measuring the
same thing (Bland & Altman, 1997).
Factor analysis of the modified NAS was computed using principal component
factor analysis, and the factors were rotated by varimax rotation. The rotation converged
in six iterations to produce four factors or subscales, explaining 40% of the variance.
Although the analysis supported some of the original clustering or grouping of items, it
showed some items belonged in a different factor (Table 8). Items loading greater than
0.30 would be included in the subscales. Items or variables loading below 0.29 were
considered for elimination.
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Table 8
Factor Loadings of the Items on the Modified Nurse’s Attitude Survey
Subscale items
19. Patients understand their prognosis and therapy goals.
18. Patients understand their plan of care/treatment.
17. Patients’ wishes regarding treatment are respected by
oncologists.
20. Patients’ prognoses are usually well explained
12. In general, patients are well informed when they choose
to participate in a clinical trial.
16. Patient’s wishes regarding treatment are respected by
nurses.
21. Patients want to be informed.
5. Clinical research improves patient care for the patient
involved.
8. Patients should be encouraged to participate in research.
11. If I had cancer, I would prefer to be treated as part of a
clinical trial.
6. Hospitals that conduct clinical research have better
standards of care than hospitals that do not.
1. Conducting research is an important role of oncologists.
4. It is appropriate for oncologists to be the person
consenting research subjects for their trials, if the research
subjects are their own clinic patients
3. It is appropriate for oncologists to invite their clinic
patients to be subjects in trials that they conduct
7. Clinical research in oncology is important in improving
standards of care in oncology
10. Nurses put too much pressure on patients to participate
in clinical trials
9. Oncologists put too much pressure on patients to
participate in clinical trials
2. Clinical research should be conducted only in cancer
centers/institutes
13. Patients are often unaware that their treatment is part of
a research protocol.
22. When being told about their therapy, most patients pay
more attention to potential benefits of therapy than side
effects.
26. Oncologists believe that patients are willing to accept
side effects for even a small benefit of therapy
23. Most patients are willing to accept side effects for even
a small benefit if therapy.
24. Patients are often frightened to ask questions.
25. Patients’ decisions whether to accept or not accept toxic
chemotherapy is strongly influenced by their family
preferences.

1
0.771
0.760
0.711

Factor loadings
2
3

4

0.689
0.530
0.492
0.312
0.682
0.612
0.572
0.541
0.534
0.463

0.456
0.339

0.751
0.724
0.419
0.413

0.702

0.662
0.611
0.504
0.361

Extraction Method: Principal Component Analysis. Rotation Method: Varimax with Kaiser Normalization. Rotation
converged in 6 iterations.
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Each item loaded strongly on one and only one factor and lends to the validity of
the subscales. A promax rotation of the principal components procedure also was
investigated to determine whether the items consistently loaded on the same factors and
to inspect the interfactor correlations. The items did load on the same factors, as in the
varimax rotation, indicating that each subscale is measuring a unique and independent
construct. The low correlation values (0.005 to 0.274) indicate very low to no correlation
or little to no linear relationship between the four subscales. Table 9 presents the
interfactor correlations for the four subscales of the instrument. With these very low
correlations in the factor analytic procedure, it is not necessary to discuss a total scale
score since the factors are measuring unique and independent constructs (DeVellis,
2003).
Table 9
Interfactor Correlation of Identified Factors

Subscale 1
Subscale 2
Subscale 3
Subscale 4

Subscale 1
1.00
0.274
0.231
0.009

Subscale 2

Subscale 3

Subscale 4

1.00
0.126
0.007

1.00
0.005

1.00

There were four subscales created: Patient Understanding and Knowledge (PUK),
Attitude Toward Clinical Research (ATCR), Roles and Location (RL), Information
Needs of Patients (INP). Table 10 illustrates the details of the four subscales created from
the factor analysis of the modified NAS.
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Table 10
Subscales Created After Factor Analysis
Subscale

No of
items

Cronbach’s
Alpha

No of items
reversed

1. Patient understanding and
knowledge (PUK)
2. Attitude towards clinical research
(ATCR)
3. Roles and location (RL)

7

0.74

0

8

0.66

0

4

0.47

4

4. Information needs of patients
(INP)

5

0.56

5

Range of
scores
SA* --SD**
SA 35 to
SD 7
SA 40 to
SD 8
SA 4 to
SD 20
SA 5 to
SD 25

*SA = strongly agree **SD = strongly disagree

Subscale 1—Patient Understanding and Knowledge
Items 12, 16, 17, 18, 19, 20, and 21 make up the Patient Understanding and
Knowledge (PUK) subscale. This subscale measured a nurse’s perception of patient
understanding and knowledge. For example, items on this subscale inquire about patients
being well informed when they participate in clinical trials (Item 12), patients
understanding their treatment plans and prognosis (Items 18, 19, and 20). The calculated
Cronbach’s alpha for the PUK subscale was 0.74, indicating the PUK subscale has a
fairly high level of internal consistency and reliability. The PUK subscale was used as the
measure for research Question 3 (see Analysis of Research Questions in this chapter)
Subscale 2—Attitudes Toward Clinical Research
Subscale 2, the Attitudes Toward Clinical Research subscale (ATCR) is
comprised of Items, 1, 3, 4, 5, 6, 7, 8, and 11. This subscale measures nurses’ general
attitudes toward clinical research. For example, the items ask about: clinical research
improving standards of care (Items 5, 6, and 7), if patients should participate in research
(Item 8), and if a person completing the instrument would participate in a clinical trial if
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they had cancer (Item 11). This subscale was the dependent variable to answer research
Question 1 (see analysis of research questions in this chapter). Cronbach’s alpha for this
scale was 0.66.
Subscale 3—Roles and Location
Four items factored together to form Subscale 3, the Roles and Location subscale
(RL), that is comprised of Items 2, 9, 10 and 13. These items measured clinical research
location and the role of oncologists and nurses in patient enrollment. For example, some
items asked if nurses or oncologists put too much pressure on patients to participate in
clinical trials (Items 9 and 10), and if clinical research should be conducted only in cancer
centers (Item 2). This subscale was used as the dependent measure for research Question
6 (see Analysis of Research Questions in this chapter). Cronbach’s alpha for this subscale
was 0.47. The alpha was not as high as the first two subscales, but it has fewer items.
Reliability is affected by the number of items in the subscale and the smaller number of
items in this subscale may be reflecting this attribute (Ary, Jacobs, & Razavieh, 2002).
Subscale 4—Information Needs of Patients
The final five items that factored together were 22, 23, 24, 25, and 26, forming the
Information Needs of Patients (INP) subscale. This subscale measured a nurse’s
perception of the informational needs of patients. Some items asked if most patients pay
more attention to potential benefits of therapy than side effects (Item 22), if oncologists
believe that patients are willing to accept side effects for even a small therapeutic benefit
(Item 26), if most patients are willing to accept side effects for even a small benefit of
therapy (Item 23), if patients are frightened to ask questions and if patients decisions are
influenced by their family preferences (Items 24 and 25). This subscale was used as the
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dependent variable to answer research Question 5 (see Analysis of Research Questions in
this chapter). The calculated Cronbach’s alpha for the INP subscale was 0.56. While the
alpha was not very high, it is acceptable for this type of measure, because the few number
of items may be affecting the reliability coefficients.
Reliability can be affected by several factors, the length of the test or number of
items on a survey; the longer it is, the greater the reliability. Reliability also is a function
of the person taking the test; a test may be reliable at one level of ability but unreliable at
another level of ability. Finally, some variables will yield consistent measures more often
than other variables. For example, academic achievement measures tend to have higher
reliability compared to softer measures such as attitudes and personality which are often
not as reliable (Ary, Jacobs, & Razavieh, 2002).
D. Analysis of Data According to Research Questions
Research Question 1
Research Question 1 - What are oncology nurses’ attitudes toward the benefits of
cancer clinical trials? This question was evaluated by the ATCR subscale. The nurses
responded to these items using a 5-point Likert scale: 1 = strongly disagree; 2 =
somewhat disagree; 3 = neither; 4 = somewhat agree and 5 = strongly agree. The
outcome variables were created by summing across the items in each subscale. The mean
summed scores were used for comparison. There are eight items that make up this
subscale and the possible average score per response are: 8 = strongly disagree, 16 =
somewhat disagree, 24 = neutral, 32 = somewhat agree, and 40 = strongly agree. The
possible range of scores is 8–40. The higher the score is, the more positive are the
attitudes of nurses toward clinical research and clinical trials.
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From this study population (N=301), 299 subjects responses were analyzed by the
ACTR subscale. The mean and median scores obtained were 32, indicating, on the
average, the oncology nurses had positive attitudes toward cancer clinical trials. When
the mean and median values are the same number, it indicates that the sample distribution
is symmetrical, as in a normal distribution curve (Stevens, 2002). The scores on the
ATCR subscale ranged from 13 to 40.
Research Question 2
Research Question 2 - What are nurses perceptions about how effective a
research drug or experimental therapy should be before it is offered to patients? This
question was evaluated by a single item on the NAS, item 15. This item states, “In your
opinion, in order for a research drug or experimental therapy to be offered to patients, it
should have at least ___________% chance of producing a desired effect (please insert a
number).” In general, before a research drug or experimental therapy is offered to a
patient, the subjects perceived that the benefit should be high, 288 (95.7%) answered this
question. Approximately half of the respondents (49.7%) believed that a research drug or
experimental therapy should have at least a 50% chance of benefiting the patient before
being offered (M = 41.57, SD = 22.76). Subjects’ answers to Item 15 ranged from 0% to
95%
Research Question 3
Research Question 3 - What are oncology nurses’ perceptions regarding patients’
understanding of clinical trials and the treatment regimen? This question was evaluated
by the PUK subscale, comprised of Items 12, 16, 17, 18, 19, 20, and 21. These items
were evaluated using a 5-point Likert scale. The outcome variables were the sum scores
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generated from the subscale, with a possible range of 7–35. Because there are seven items
on this subscale, the possible average scores are: 7 = strongly disagree, 14 = somewhat
disagree, 21 = neutral, 28 = somewhat agree, and 35 = strongly agree. A higher score
suggests that nurses are more likely to believe that patients are well informed about
clinical trials, understand the treatment regimen, and desire to be informed.
All 301 subjects completed the items on the PUK subscale. The mean score was
27.6, and the median was 28, indicating this group of oncology nurses agreed that
patients are well informed about clinical trials, understand the treatment regimen, and
desire to be informed. The mean and median scores are nearly identical indicating that
the distribution of data are nearly symmetrical and follow a normal distribution curve
(Stevens, 2002).
Research Question 4
Research Question 4 - What factors do nurses perceive influence a patient’s
decision to participate in a cancer clinical trial? This question was evaluated by Item14
on the NAS. The item asks, “Patients participate in research because of,” and there are 10
subitems (letters A-J), with corresponding evaluations using a 5-point Likert scale. The
10 subitems were ranked from highest to lowest according to the percentage of subjects
who selected number 4 or 5 (somewhat agree or strongly agree) on the Likert scale.
Ninety-three percent of nurses thought that patients participated in research with the
expectation of cure; 87% reported that patients participated as a desire to help others;
86% thought patients wanted an improved quality of life (see Table 11).
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Table 11
Nurses’ Perceptions of Patient Motivation for Participation in Clinical Trials (N = 301)
Motivation
Wish for cure

n
280

%
93

Wish to help others

262

87

Wish for improved quality of life

261

86

Hope for better medical care

229

76

No other option

219

73

Inability to accept that nothing else can be done

187

62

Family wishes

169

56

Inability to accept death

158

53

Desire to please their oncologist

85

28

Pressure from oncologist

39

13

Research Question 5
Research Question 5 - What are nurses’ perceptions of patients’ decision-making
processes and the desire for information regarding clinical trial participation? This
question was addressed by Items 22, 23, 24, 25, and 26 of the INP subscale. After
completing the factor analysis to confirm the items relationship with each other, the
outcome variables were sum scored with a possible range of 5–25. The items on the INP
scale were reverse coded (strongly agree = 1, somewhat agree = 2, neutral = 3, somewhat
disagree = 4, and strongly disagree = 5). The possible scores for each Likert item follows:
5 = strongly agree, 10 = somewhat agree, 15 = neutral, 20 = somewhat disagree, and 25 =
strongly disagree, with a lower score suggesting that nurses perceive that patients have
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enough information to make decisions regarding clinical trial participation. The minimum
score on the INP subscale was 5 and the maximum 19. From the entire study population
(N = 301), 299 (99.3%) responded to the items on the INP subscale. The mean score
obtained was 10.9, and the median was 11, indicating that on average, this group of
oncology nurses perceived that patients have enough information to make decisions
regarding clinical trial participation. The mean and median scores almost are identical
indicating that the distribution of data is nearly symmetrical and follows a normal
distribution curve (Stevens, 2002).
Research Question 6
Research Question 6 - What are the perceptions of nurses regarding where
clinical research should be conducted and the role of oncologists and nurses in clinical
trials? This question was evaluated by the RL subscale, consisting of items 2, 9, 10, and
13. A 5-point Likert scale was used for these items. Items on the subscale were reverse
coded, with strongly agree = 1, somewhat agree = 2, neutral = 3, somewhat disagree = 4,
and strongly agree = 5. The outcome variables were sum scored with possible range of 4–
20. The possible average scores for each item are; 4 = strongly agree, somewhat agree =
8, neutral = 12, somewhat disagree = 16, and strongly disagree = 20. A lower score
suggests agreement with the items on the subscale, such as clinical research should be
conducted only in cancer centers, oncologists and nurses put too much pressure on
patients to participate in clinical trials, and patients often are unaware that their treatment
is part of a research protocol. Three hundred of the 301 subjects responded to the items
on the RL subscale. The mean score was 15.4, and the median was 16, indicating this
group of oncology nurses somewhat disagreed that clinical research should be conducted
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only in cancer centers, oncologists and nurses put too much pressure on patients to
participate in clinical trials, and patients often are unaware that their treatment is part of a
research protocol. Consistent with the scores obtained on the ATCR, PUK, and INP
subscales, the mean and median scores nearly are identical, indicating that the data follow
a normal distribution curve (Stevens, 2002).
Research Question 7
Question 7 - Do the independent variables of nurses’ age, education level,
whether nurses directly work with clinical trial patients, number of years in oncology,
primary work setting, and their primary position serve as significant predictors related to:
1. Attitudes toward the benefits of cancer clinical trials, measured by ATCR
subscale?
2. Attitudes about how effective a research drug or experimental therapy should
be shown to be before it is offered to patients, measured by Item 15 on the NAS?
3. Perceptions regarding patients’ understanding of clinical trials and the
treatment regimen, as measured by the PUK subscale?
4. Perceptions of patients’ decision-making processes and the desire for
information regarding clinical trial participation, as measured by the INP subscale?
5. Perceptions regarding where clinical research should be conducted, patients’
awareness of their treatment, and the role of oncologists and nurses in clinical trials, as
measured by the RL subscale?
Oncology nurses’ attitudes toward the benefit of cancer clinical trials were
evaluated by the ATCR subscale. Using the stepwise multiple regression method, nurse’s
primary position entered the stepwise regression model as a significant predictor of

90
attitudes toward cancer clinical trials (as measured by the ATCR subscale), controlling
for the other independent variables, F (1, 228) = 37.555, p <0.001. However, the R2 =
0.141, indicated the model accounted for only 14.1% of variance in attitude scores. The β
coefficient is 0.376, indicating primary position has a low effect on the ATCR subscale;
however, the effect was statistically significant (t = 6.128, p<0.001) (see Table 12).
Table 12
Table 12 Stepwise Regression Model Summary for ATCR subscale
Predictor
Primary
position
Primary
position

R
0.378

R2
0.141

R2adj
0.138

B
1.466

β
0.376

t
6.128

Fchg
37.555

p
<0.001

p
<0.001

ANOVA demonstrated statistically significant differences between the mean
scores of nurses grouped within the primary position variable, F (3,248) = 10.322, p =
0.000 (Table 13). This group included staff nurses, clinical trials nurses (CTN) , clinical
nurse specialist/nurse practitioners (CNS/NP) and “other.”
Table 13
ANOVA for Primary Position and ATCR Subscale
Groups
(Primary position)
Staff nurse
CNS/NP
CTN
Other

N
114
80
17
41

M

SD

df

F

P

30.5
32.0
33.6
34.1

4.2
4.0
2.9
3.5

3, 248

10.322

0.000

A Bonferroni post-hoc multiple comparisons test between the primary position
variables was conducted to determine which groups had statistically significant
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differences in their mean ATCR scores (Table 14). CTN had statistically significant
higher scores compared to staff nurses (p = 0.014) only. Nurses in “other” positions had
significantly higher scores on the ATCR, compared to staff nurses and CNS/NP (p =
0.000 and 0.026, respectively).
Table 14
Bonferroni Multiple Comparisons for Primary Position and ATCR Subscale
Dependent
variable
ATCR subscale

(I) Primary
position
Staff nurse

CNS/NP

CTN

Other

(J) Primary
position
CNS/NP
CTN
Other
Staff nurse
CTN
Other
Staff nurse
CNS/NP
Other
Staff nurse
CNS/NP
CTN

Mean
difference
(I-J)
-1.4750
-3.1471(*)
-3.6463(*)
1.4750
-1.6721
-2.1713(*)
3.1471(*)
1.6721
-0.4993
3.6463(*)
2.1713(*)
0.4993

Std.
error

P

0.5734
1.0222
0.7160
0.5734
1.0500
0.7551
1.0222
1.0500
1.1341
0.7160
0.7551
1.1341

0.064
0.014
0.000
0.064
0.675
0.026
0.014
0.675
1.000
0.000
0.026
1.000

* The mean difference is significant at < 0 .05 level.

Even though work setting was not a predictive variable for the ATCR subscale,
nurses grouped by this setting also had significant differences in their ATCR scores, F
(5,262) = 5.156, p = 0.000 (see Table 15). This group included bone marrow
transplant/intensive care unit nurses (BMTU/ICU), in-patient medical-surgical oncology
unit and oncology specialty unit nurses (MSOU), hospital based clinic/infusion center
nurses (HBIC), corporate/industry nurses (CI), and “other.”
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Table 15
ANOVA for Primary Work Setting and ATCR Subscale
Groups
(work setting)

N

M

SD

BMTU/ICU
MSOU
HBIC
MDO
CI
Other

15
79
55
45
26
56

30.7
30.9
32.2
31.3
35.0
33.0

2.6
4.2
4.3
4.5
3.3
3.6

df

F

P

5, 262 5.156 0.000

To determine which of the five different practice setting groups had significant
differences in their ATCR subscale scores, the data were analyzed with a Bonferroni
post- hoc multiple comparison test. Nurses who reported that they work in a
corporate/industry (CI) work setting had significantly higher scores on the ATCR (M =
35.0) compared to BMTU/ICU nurses (M = 30.7, p = 0.019), medical-surgical oncology
unit (MSOU) nurses (M = 30.9, p = 0.000), and physician office (MDO) nurses (M =
31.3, p = 0.003). Table 16 presents the results of the Bonferroni pairwise comparisons for
primary work setting.
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Table 16
Bonferroni Multiple Comparisons for Primary Work Setting and ATCR Subscale
Dependent
(I) Work
(J) Work
Mean
Std.
P
variable
setting
setting
difference
error
(I-J)
ATCR

BMTU/ICU

MSOU

HBIC

MDO

CI

Other

MSOU
HBIC
MDO
CI
Other
BMTU/ICU
HBIC
MDO
CI
Other
BMTU/ICU
MSOU
MDO
CI
Other
BMTU/ICU
MSOU
HBIC
CI
Other
BMTU/ICU
MSOU
HBIC
MDO
Other
BMTU/ICU
MSOU
HBIC
MDO
CI

-0.2111
-1.4519
-0.5333
-4.2282(*)
-2.2488
0.2111
-1.2407
-0.3222
-4.0171(*)
-2.0377
1.4519
1.2407
0.9185
-2.7764
-0.7970
0.5333
0.3222
-0.9185
-3.6949(*)
-1.7155
4.2282(*)
4.0171(*)
2.7764
3.6949(*)
1.9794
2.2488
2.0377
0.7970
1.7155
-1.9794

1.1342
1.1663
1.1914
1.2956
1.1618
1.1342
0.7194
0.7594
0.9143
0.7120
1.1663
0.7194
0.8066
0.9539
0.7621
1.1914
0.7594
0.8066
0.9844
0.8000
1.2956
0.9143
0.9539
0.9844
0.9483
1.1618
0.7120
0.7621
0.8000
0.9483

1.000
1.000
1.000
0.019
0.810
1.000
1.000
1.000
0.000
0.068
1.000
1.000
1.000
0.059
1.000
1.000
1.000
1.000
0.003
0.494
0.019
0.000
0.059
0.003
0.567
0.810
0.068
1.000
0.494
0.567

* The mean difference is significant at < 0 .05 level.

Item 15 on the NAS asked subjects their perceptions on the effectiveness
(expressed in percent benefit) of a research drug or experimental treatment before it is
offered to patients. The multiple regression analysis revealed a significant model, primary
position, years experience as a cancer RN, work setting, and educational level were
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predictors of the nurse’s opinion of the effectiveness of a research drug or experimental
treatment before being offered to a patient, F (4, 218) = 9.164, p = 0.000 . However, the
R2 was 0.144, indicating the model has accounted for only 14.4% of the variance in
perceived benefit estimates (see Table 17).
Table 17
Stepwise Regression Model Summary for Perception of Benefit
Predictor
Primary position
Years cancer RN
Work setting
Education level

R
0.379

R2
0.144

R2adj
0.128

Fchg
4.373

p
0.038

Despite this model being statistically significant for predicting the opinion of the
perceived benefit of the effectiveness a research drug or experimental treatment should
have before being offered to a patient, the β regression coefficients were low for each
predictor variable (see Table 18). This indicates primary position, years in cancer
nursing, work setting, and education level had a low effect on the perceived benefit. Only
the effect of years a cancer RN, work setting, and education level were statistically
significant (t = 2.091, p = 0.038; t = 2.417, p = 0.016; t = 2.091, p = 0.038 respectively).
Table 18
Stepwise Regression Coefficients for Perception of Benefit Model

Primary position
Years cancer RN
Work setting
Education level

B
-2.783
-0.373
-2.578
-1.519

β
-0.127
-0.137
-0.172
-0.144

t
1.701
2.091
2.417
2.091

P
0.090
0.038
0.016
0.038
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In addition to the variables of primary position, years as a cancer RN, work setting and
educational level, being predictors of the nurses’ perceptions of the benefit of
effectiveness a research drug or experimental treatment should have before being offered
to a patient, statistically significant differences were found between these groups of
nurses’ responses when ANOVA was performed.
Primary position. Staff nurses reported the highest perception of benefit regarding
the effectiveness of a research drug or experimental therapy, before being offered to
patients compared to nurses in other positions. According to the results from the ANOVA
of primary position and the opinion of the benefit of an experimental treatment before
being offered as part of cancer therapy, there were statistically significant differences in
this group F (3, 239) = 8.499, p = 0.000 (see Table 19).
Table 19
ANOVA of Primary Position and Perception of Benefit
Groups
(Primary Position)
Staff nurse

N

M
%

SD

Df

3, 239

114

49.3

22.6

CNS/NP

74

34.6

21.1

CTN

16

36.3

26.3

Other

39

35.1

21.2

F

P

8.499

0.000

The investigator performed a Bonferroni multiple comparisons for primary
position and nurse’s opinion of the effectiveness of a research drug or experimental
therapy before being offered to a patient (see Table 20). Staff nurses had significantly
higher perceptions of the benefit a research drug or experimental therapy should have
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before being offered to patients, compared to CNS/NPs (p = 0.000) and nurses in “other”
positions (p = 0.004), but not between any other positions (see Table 20).
Table 20
Bonferroni Multiple Comparisons for Primary Position and Perception of Benefit
Dependent
variable

(I) Primary
position

(J) Primary
position

Perception of
Benefit

Staff nurse

CNS/NP

CTN

Other

CNS/NP

Mean
difference
(I-J)
14.72(*)

Std.
error

P

3.31

0.000

CTN
Other
Staff nurse
CTN
Other
Staff nurse
CNS/NP
Other
Staff nurse
CNS/NP
CTN

13.09
14.29(*)
-14.72(*)
-1.63
-0.43
-13.09
1.63
1.20
-14.29(*)
0.43
-1.20

5.93
4.12
3.31
6.12
4.39
5.93
6.12
6.59
4.12
4.39
6.59

0.169
0.004
0.000
1.000
1.000
0.169
1.000
1.000
0.004
1.000
1.000

* The mean difference is significant at < 0 .05 level.

Number of years in cancer nursing. Nurses with 10 or less years of experience
had the highest perception of benefit of cancer therapy prior to being offered as part of
research. This group reported that a research drug, or experimental therapy, should have
at least a 46.2% (mean) chance of producing a desired effect before being offered to
patients. In contrast, nurses with greater than 20 years experience in cancer nursing had
the lowest perceived benefit. They reported that a therapy should have at least a 35%
(mean) chance of producing the desired effect. Nurses with 11-20 years of experience in
cancer nursing reported a research drug, or experimental therapy, should have at least a
40.2% (mean) chance of producing the desired effect. The ANOVA for number of years
in cancer nursing and perceptions regarding the effectiveness of cancer therapy offered as
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part of research revealed statistically significant differences between the three groups F
(2, 281) = 5.318, p = 0.005 (see Table 21).
Table 21
ANOVA for Number of Years in Cancer Nursing and Perception of Benefit
Groups
(Years a cancer
RN)
<1–10
11–20
>20

N

M
%

SD

df

F

P

130
98
56

46.2
40.2
35.1

22.2
23.1
21.2

2, 281

5.318

0.005

In order to examine which group had statistically significant differences in their
perception of benefit a research drug or experimental therapy should have before being
offered to patients, a Bonferroni multiple comparisons test was performed (see Table 22).
This test revealed that nurses with greater than 20 years experience had a statistically
significant difference in their opinion compared to nurses with 10 years or less
experience (p = 0.006), but not with nurses who had 11–20 years experience (p = 0.522).
Moreover, there was no a statistically significant difference in the opinions of nurses with
10 or less years experience compared to nurses with 11–20 years experience (p = 0.134).
Table 22
Bonferroni Multiple Comparisons for Years in Cancer Nursing and Perception of Benefit
Dependent
variable
Perception of
Benefit

(I) Yrs CN

(J) Yrs CN

<1-10

11-20
>20

11-20

Mean
difference (I-J)
6.03

Std.
error
2.99

0.134

>20
<10
>20
<1-10
11-20

11.12(*)
-6.03
5.10
-11.12(*)
-5.10

3.57
2.99
3.74
3.57
3.74

0.006
0.134
0.522
0.006
0.522

* The mean difference is significant at < 0 .05 level.

P
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Primary work setting.

There were statistically significant differences found in the

responses of the subjects, grouped by work setting, regarding the desired effect a research
drug, or experimental therapy should have, before being offered to patients in the subjects
grouped by work setting F (5, 253) = 6.450, p = 0.000 (see Table 23).
Table 23
ANOVA of Primary Work Setting and Perception of Benefit
Groups
(work setting)
BMTU/ICU
MSOU
HBIC
MDO
CI
OTHER

N
14
71
51
46
25
52

M
%
48.9
51.4
35.1
41.2
27.2
39.0

SD

Df

24.4
22.6
20.1
23.8
21.6
19.4

5, 253

F
6.450

P
0.000

The nurses who reported that they worked in a corporate /industry (CI) setting had
perceived a lower benefit (M = 27.2%) of the effectiveness a research drug or
experimental therapy should have before being offered to patients, compared to all other
nurses in this group. Furthermore, nurses who reported that they worked in an inpatient
setting on a medical-surgical oncology unit or an oncology specialty unit (MSOU) had
the highest perceived benefit (M = 51.4%), compared to other nurses in this group
Nurses working in an inpatient setting on MSOU had a statistically significant
higher perception of benefit of the effectiveness a research drug or experimental therapy
should have before being offered to patients, compared to HBIC nurses (p = 0.001), to
nurses in a CI setting (p = 0.000) and to nurses in other settings (p = 0.030). Nurses
working in BMTU/ICU as well as MSOU nurses statistically had a significant higher
perception compared to nurses in a corporate/industry setting (p = 0.045 and p = 0.000,
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respectively). All other comparisons between the groups were not statistically significant
(see Table 24).
Table 24
Bonferroni Multiple Comparisons for Work Setting and Perception of Benefit
Dependent
variable

(I) Work
setting

(J) Work
setting

Opinion

BMTU/ICU

MSOU
HBIC
MDO
CI
Other
BMTU/ICU
HBIC
MDO
CI
Other
BMTU/ICU
MSOU
MDO
CI
Other
BMTU/ICU
MSOU
HBIC
CI
Other
BMTU/ICU
MSOU
HBIC
MDO
Other
BMTU/ICU
MSOU
HBIC
MDO
CI

MSOU

HBIC

MDO

CI

OTHER

Mean
difference
(I-J)
-2.44
13.87
7.75
21.73(*)
9.95
2.44
16.31(*)
10.19
24.17(*)
12.39(*)
-13.87
-16.31(*)
-6.12
7.86
-3.92
-7.75
-10.19
6.12
13.97
2.19
-21.73(*)
-24.17(*)
-7.86
-13.97
-11.78
-9.95
-12.39(*)
3.92
-2.19
11.78

Std.
error
6.36
6.56
6.64
7.26
6.55
6.36
3.99
4.11
5.06
3.97
6.56
3.99
4.42
5.31
4.28
6.64
4.11
4.42
5.40
4.40
7.26
5.06
5.31
5.40
5.29
6.55
3.97
4.28
4.40
5.29

P

1.000
0.532
1.000
0.045
1.000
1.000
0.001
0.209
0.000
0.030
0.532
0.001
1.000
1.000
1.000
1.000
0.209
1.000
0.154
1.000
0.045
0.000
1.000
0.154
0.403
1.000
0.030
1.000
1.000
0.403

* The mean difference is significant at <0.05 level.

Education level. Nurses with a bachelor’s degree had the highest perception of
benefit of a research drug or experimental treatment producing a desired effect before
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being offered to patients (M = 47.4%, SD = 22.3), compared to other nurses in this
sample. In contrast, nurses with a master’s degree or higher indicated the lowest
perception of the three groups (M = 35.6%, SD = 21.1). There was a statistically
significant difference in the responses of the three groups according to education
preparation F (2, 284) = 8.087, p = 0.000 (see Table 25).
Table 25
ANOVA for Educational Level and Perception of Benefit
Education groups
Diploma or associate’s
Bachelor’s degree
Master’s or higher

N
86
79
122

M%
45.0
47.4
35.6

SD

df

23.6
22.3
21.1

2, 284

F
8.8087

P
0.000

Nurses with a master’s degree or higher statistically had a significant difference in
their mean responses when compared to nurses with a bachelors degree and nurses with
any degree less than a bachelor’s (p = 0.001, p = 0.009, respectively). This result
indicates that nurses with a master’s degree or higher perceived the least necessary
benefit compared to other nurses with lesser educational degrees. They reported a
research drug or experimental therapy should have a 35.6% (mean) chance of producing a
desired effect before being offered to patients (see Table 26).
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Table 26
Bonferroni Multiple Comparisons for Education Level and Perception of Benefit
Dependent
variable

(I) Education groups

Perception of
Benefit

Diploma or associates Bachelor’s

Bachelor’s

Master’s or higher

(J) Education
groups

Master’s or
higher
Diploma or
associates
Master’s or
higher
Diploma or
associates
Bachelor’s

Mean
difference
(I-J)
-2.41

Std.
error

P

3.46

1.000

9.34(*)

3.13

0.009

2.41

3.46

1.000

11.76(*)

3.21

0.001

-9.34(*)

3.13

0.009

11.76(*)

3.21

0.001

* The mean difference is significant <0.05 level

Nurse’s perception of patient knowledge and understanding of the treatment
regimen was evaluated by the PUK subscale. Multiple regression analysis revealed
nurse’s education level, work setting, and whether they work with clinical trial patients or
not were significant predictors of their perceptions of patient knowledge and
understanding, F (3, 228) = 4.846, p = 0.003. The R2 was 0.060, indicating the model
accounted for only 6% of the variance in perceptions (see Table 27).
Table 27
Stepwise Regression Model Summary for PUK subscale
Predictors
Education level,
Work setting,
Trials

R
0.245

R2
0.060

R2adj
0.048

Fchg
5.705

p
0.018

The β regression coefficients for the model were low (see Table 28), indicating
educational level, work setting, and working with clinical trial patients or not had a low
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effect on perceptions. However, the effect of education level, work setting and whether
they work with clinical trial patients or not was significant (t = 2.432, p = 0.016; t =
2.442, p = 0.015; and t = 2.388, p = 0.00018, respectively).
Table 28
Stepwise Regression Coefficients for PUK Model

Ed level
Work setting
Trials

B
-0.274
0.394
1.605

β
- 0.158
0.159
0.155

t
2.432
2.442
2.388

P
0.016
0.015
0.00018

Despite education level being a significant predictor for oncology nurses’
perceptions regarding patients’ understanding of clinical trials and the treatment regimen,
there were no significant differences between the scores on the PUK subscale in this
group. However, after performing ANOVA for nurses working with clinical trial patients
or not, and nurses grouped by work setting revealed significant differences in their scores
on the PUK subscale.
Working with clinical trial patients. Nurses who work with clinical trial patients
had a higher mean score on the PUK subscale compared to nurses who do not (27.9 and
26.5, respectively), indicating that nurses who work with clinical trial patients perceive
patients understand their treatment goals, plan, and prognosis, and their wishes are
respected by oncologists and nurses. The differences in their scores were statistically
significant, F (1, 298) = 5.292, p = 0.022 (see Table 29).
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Table 29
ANOVA for Working with Clinical Trial Patients or Not and PUK Subscale
Groups

N

M

SD

Df

No
Yes

51
249

26.5
27.9

4.5
3.6

1,298

F

P

5.292

0.022

Work setting. Two groups of nurses reported they worked in an outpatient setting,
HBIC and MDO nurses, had higher scores on the PUK (28.8 and 28.2, respectively)
compared to the other nurses. This result suggests HBIC and MDO nurses perceive that
patients are well informed when they participate in clinical trials and patients understand
their treatment plan and prognosis, compared to BMTU/ICU, MSOU, and CI nurses. The
nurses working in BMTU/ICU, MSOU, CI and nurses in other settings all had similar
scores on the PUK (26.2, 27.0, 26.5, and 28.0, respectively). ANOVA was calculated for
differences between the subjects grouped by work setting and a statistically significant
difference was found, F (5, 264) = 2.516, p = 0.030 (see Table 30).
Table 30
ANOVA for Work Setting and PUK Subscale
Groups
(work setting)

N

M

SD

df
5, 264

BMTU/ICU

15

26.2

3.8

MSOU

73

27.0

4.0

HBIC
MDO
CI
Other

54
46
26
56

28.2
28.8
26.5
28.0

3.6
4.1
4.3
3.2

F
2.516

P
0.030
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Despite finding a statistically significant difference in the groups’ scores by
ANOVA, surprisingly the Bonferroni post-hoc multiple comparisons test failed to
identify which group differed from which. This discrepancy may be explained by two
factors. First, the variance between groups is not big enough to make a difference. With
unequal sample sizes within each group, the small differences between groups may be
cancelled in the post-hoc, pairwise comparisons. Secondly, the more groups that have a
large variation in sample size, the harder it is to detect significant differences between
groups, especially with a rigorous and conservative test such as Bonferroni to avoid type
I error (Keppel & Wickens, 2002).
The INP subscale measured nurse’s perceptions of patients’ perceptions of the
treatment and research process and influences in patients’ decisions. As stated above, the
items on this subscale were reverse coded (strongly agree = 1, somewhat agree = 2,
neutral = 3, somewhat disagree = 4, and strongly disagree = 5) with a lower score
suggesting that nurses perceive that patients have enough information to make decisions
regarding clinical trial participation.
The multiple regression analysis revealed a significant model, whether nurses
work with clinical trials patients or not, F (1, 228) = 5.798, p =.017. The R2 = 0.025,
indicating the model accounted for only 2.5% of the variance in perceptions (see Table
31).
Table 31
Stepwise Regression Model Summary for INP Scale
Predictor
Trials

R
0.157

R2
0.025

R2adj
0.021

Fchg
5.798

p
0.017
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The β regression coefficient for the predictor variable was 0.157 (see Table 32).
This indicates that the variable (nurse’s working with clinical trial patients or not) had a
low effect on perceptions, as measured by the INP subscale despite a statistically
significant multiple regression model.
Table 32
Stepwise Regression Coefficients for INP Model
Predictor
Trials

B
1.058

β
0.157

t
2.408

P
0.017

Nurses grouped by whether or not they work with clinical trial patients was the
only significant predictor of perceptions of patients’ decision-making process and desire
for clinical trial information. However, in evaluating differences in the mean scores
among the oncology nurses in this study grouped by the independent variables,
statistically significant differences were found in this group and nurses grouped by work
setting.
Working with clinical trial patients. Nurses who reported that they do not work
with or care for clinical trial patients had a lower score (M = 10.1), compared to nurses
who do (M = 11.0). This result suggests nurses who do not work with clinical trial
patients perceive that most patients pay more attention to potential benefits of therapy
than side effects, oncologists believe that patients are willing to accept side effects for a
small therapeutic benefit, patients are frightened to ask questions, and patients’ decisions
are influenced by their family’s preferences, compared to nurses who do work with
clinical trial patients. This difference was statistically significant, F (1, 296) = 5.872, p =
0.016 (see Table 33).
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Table 33
ANOVA for Working with Clinical Trial Patients or Not and INP Subscale
Groups
No
Yes

N

M

SD

df

F

P

50
248

10.1
11.0

2.4
2.6

1, 296

5.872

0.016

Work setting. There were statistically significant differences in the scores on the
INP subscale between nurses based upon their work setting, F (5, 262) = 2.762, p = 0.019
(see Table 34).
Table 34
ANOVA for Work Setting and INP Subscale
INP
subscale

Groups
work setting
BMTU/ICU
MSOU
HBIC
MDO
CI
Other

N

M

SD

Df

F

P

15
73
54
45
26
55

9.5
10.8
11.0
11.9
10.9
10.5

2.6
2.2
2.5
3.0
2.5
2.6

5, 262

2.762

0.019

Nurses working in BMTU/ICU had a lower score (M = 9.5) on the INP subscale
compared to all other nurses by work setting. This indicates that BMTU/ICU nurses
perceive, more than the other four groups, that patients are willing to accept side
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effects, pay more attention to the benefits of therapy, have their decisions influenced by
their families and are frightened to ask questions. There were statistically significant
differences in the scores of BMTU/ICU nurses (M = 9.5) compared to MDO nurses (M =
11.9, p = 0.025). There were no statistically significant differences in the mean scores of
the other subjects (see Table 35).
Table 35
Bonferroni Multiple Comparisons for Work Setting and INP Subscale
Dependent
variable

(I) Work
setting

(J) Work setting

INP Subscale

BMTU/ICU

MSOU
HBIC
MDO
CI
Other
BMTU/ICU
HBIC
MDO
CI
Other
BMTU/ICU
MSOU
MDO
CI
Other
BMTU/ICU
MSOU
HBIC
CI
Other
BMTU/ICU
MSOU
HBIC
MDO
Other
BMTU/ICU
MSOU
HBIC
MDO
CI

MSOU

HBIC

MDO

CI

Other

* The mean difference is significant at <0.05 level

Mean
difference (IJ)
-1.2475
-1.4481
-2.4000(*)
-1.3513
-0.9212
1.2475
-0.2007
-1.1525
-0.1038
0.3263
1.4481
0.2007
-0.9519
9.687E-02
0.5269
2.4000(*)
1.1525
0.9519
1.0487
1.4788
1.3513
0.1038
-9.6866E-02
-1.0487
0.4301
0.9212
-0.3263
-0.5269
-1.4788
-0.4301

Std. error

0.7171
0.7383
0.7541
0.8201
0.7368
0.7171
0.4540
0.4794
0.5777
0.4516
0.7383
0.4540
0.5106
0.6038
0.4846
0.7541
0.4794
0.5106
0.6231
0.5084
0.8201
0.5777
0.6038
0.6231
0.6020
0.7368
0.4516
0.4846
0.5084
0.6020

P

1.000
0.763
0.025
1.000
1.000
1.000
1.000
0.254
1.000
1.000
0.763
1.000
0.951
1.000
1.000
0.025
0.254
0.951
1.000
0.059
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
0.059
1.000
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The RL subscale evaluated nurses’ perception of patients’ awareness of their treatment
and the role of oncologists and nurses in clinical trials. As with the INP subscale, the RL
subscale was reverse coded (strongly agree = 1, somewhat agree = 2, neutral = 3, somewhat
disagree = 4, and strongly disagree = 5) with a lower score suggesting that nurses perceive
clinical research should only be conducted primarily in cancer centers, oncologists and nurses
put too much pressure on patients to participate in clinical trials, and that patients often are
unaware that their treatment is part of a research protocol.
The multiple regression demonstrated that, years of experience as a cancer RN and
whether a nurse works with clinical trial patients as predicators of the perception measured by
the RL subscale, F (2, 229) = 6.813, p=.001. The R2 = 0.056 indicating the predictor variables
accounted for only 5.6% of the variance of perceptions (see Table 36).
Table 36
Stepwise Regression Model Summary for RL Subscale
Predictors
Years cancer RN
Trials

R
0.237

R2
0.056

R2adj
0.048

Fchg
4.630

p
0.032

The β regression coefficients for the predictor variables of years experience as a cancer
RN and whether a nurse worked with clinical trial patients were low (0.182 and 0.139,
respectively) (see Table 37). This indicates that while there was statistical significance of the
predictor variables, the variables had a low effect on the measurement of perceptions measured
by the RL subscale. However, the effect was statistically significant for number of years as a
cancer RN and whether or not nurses work with clinical trial patients (t = 2.830, p = 0.005 and
t = 2.152, p = 0.32, respectively).
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Table 37
Stepwise Regression Coefficients for RL Model
Predictors
Years cancer RN
Trials

B
0.0056
0.977

β
0.182
0.139

t
2.830
2.152

P
0.005
0.032

There were significant differences in the mean scores measured by the RL subscale in the
nurses grouped by years as a cancer RN and whether or not nurses work with clinical trial
patients, but not in any other variables.
Working with clinical trial patients. The ANOVA for this variable demonstrated a
statistically significant difference in mean scores of nurses who do and do not work with
clinical trial patients, F (1,297) = 10.165, p = 0.002 (see Table 38).
Table 38
ANOVA for Working With Clinical Trial Patients or Not and RL Subscale
RL subscale

Groups
No
Yes

N

M

SD

df

F

51
248

14.4
15.6

2.8
2.5

1, 297 10.165

P
0.002

Nurses who do not work with or care for clinical trial patients had lower scores on the
RL subscale (M = 14.4), compared to nurses who do (M = 15.6). This result suggests nurses
who do not work with clinical trial patients perceive that clinical research should be conducted
only in cancer centers, oncologists and nurses put too much pressure on patients to participate
in clinical trials, and patients are often unaware that their treatment is part of a research
protocol, compared to nurses who do work with clinical trial patients.
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Years experience in cancer nursing. Nurses with less that one to ten years of
experience in cancer nursing had lower scores on the RL subscale (M = 14.8), compared to
nurses with nurses with 11-20 years of experience (M = 15.8) and nurses with greater than 20
years of experience (M = 15.9). The differences between groups were statistically significant as
measured by ANOVA, F (2,294) = 6.027, p = 0.003 (see Table 39).
Table 39
ANOVA for Years in Cancer Nursing and RL Subscale
RL subscale

Groups
years a cancer RN

N

M

SD

df

F

<1–10
11–20
>20

136
98
62

14.8
15.8
15.9

2.7
2.6
2.4

2, 294

6.027

P
0.003

Nurses with less that one to ten years of experience in cancer nursing had a statistically
significant difference in their mean score on the RL subscale, compared to nurses with 11–20
years of experience and nurses with greater than 20 years of experience (p = 0.013, p = 0.014,
respectively). Nurses with <1-10 years experience, on average, perceived that clinical research
should be conducted only in cancer centers, oncologists and nurses put too much pressure on
patients to participate in clinical trials, and patients are often unaware that their treatment is
part of a research protocol, compared to nurses with 11 years or greater experience in cancer
nursing (see Table 40).

111
Table 40
Bonferroni Multiple Comparisons for Years in Cancer Nursing and RL Subscale
Dependent
variable
RL Subscale

(I) Years cancer
RN

(J) Years cancer
RN

<1–10

11–0
>20
<1–10
>20
<1–10
11–20

11–20
>20

Mean
difference
(I-J)
-0.9696(*)
-1.1049(*)
0.9696(*)
-0.1353
1.1049(*)
0.1353

Std.
error

P

0.3361
0.3888
0.3361
0.4122
0.3888
0.4122

0.013
0.014
0.013
1.000
0.014
1.000

* The mean difference is significant at <0.05 level.

Additional Information
The following information was not part of the research questions; however, interesting
data related to individual items within the subscales were found. Although 98.3% of the
subjects agreed that clinical research was important in improving future standards of care and
75.4% agreed that patients should be encouraged to participate in research, only 51.5% of
subjects responded that they would prefer treatment in a clinical trial if they had cancer.
The nurses in this study drew distinctions between themselves and oncologists in terms
of patient decision-making. Ninety-eight percent of the nurses stated that nurses respected
patients’ wishes, whereas 82.7% thought that oncologists respected patients’ wishes. Overall,
8.6% of the nurses agreed with the statement “oncologists put too much pressure on patients to
participate in clinical trials.” Only 3.3% of the nurses agreed with the statement that “nurses
put too much pressure on patients to participate in clinical trials.”
The nurses expressed minor concern about patients’ understanding of treatment and
prognosis. Approximately three quarters of the nurses perceived that patients understand their
plan of care (76.4%). Eighty-seven percent of all nurses thought that patients want to be
informed, and 80.7% thought that patients actually were well informed when they chose to
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participate in a clinical trial. Twenty percent of the nurses disagreed, and 68% agreed with the
statement “patients understand their prognosis and goals of therapy.” Only 58% of the nurses
agreed that patients’ prognosis are well explained to them. Overall, 11% of the nurses agreed
with the statement “patients are often unaware that their treatment is part of a research
protocol.” Finally, 66% of the nurses responded that patients are frightened to ask questions.
E. Summary of Results
The nurses in this study, on average, had positive attitudes toward cancer clinical trials.
They perceived high benefit levels were necessary before a research drug or experimental
therapy is being offered to patients. Approximately half of the respondents (49.7%) believed
that an experimental therapy should have at least a 50% chance of producing a desired effect,
before being offered to patients. In general, the nurses perceived that patients are well informed
about clinical trials, understand the treatment regimen, and have a desire to be informed. On
average, this group of oncology nurses perceived that patients have enough information to
make decisions regarding clinical trial participation. They somewhat disagreed that; clinical
research should be conducted only in cancer centers, oncologists and nurses put too much
pressure on patients to participate in clinical trials, and patients are often unaware that their
treatment is part of a research protocol.
Stepwise multiple regression models found the following significant predictors to
attitudes and perceptions. Primary position was a significant predictor for attitudes toward
cancer clinical trials as measured by the ATCR subscale. CTN had more positive attitudes
compared to staff nurses, but not other nurses in this group. Nurses in “other” positions had
more positive attitudes compared to staff nurses and CNS/NP. Additionally, nurses who
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reported that they work in a CI work setting had more positive attitudes toward cancer clinical
trials compared to BMTU/ICU nurses, MSOU nurses, and MDO nurses.
Primary position, years as a cancer RN, work setting and educational level were
significant predictors of the perception of the benefit a cancer therapy should offer if included
in a clinical trial. Staff nurses had the highest expectations regarding the effectiveness of
cancer therapy offered as part of a clinical trial, compared to nurses in other positions. The
differences were statistically significant between staff nurses compared to CNS/NPs and nurses
indicating “other” as position on the DIF, but not among any other nursing positions.
Nurses with 10 or fewer years of experience as a nurse in cancer care had the highest
perception of benefit regarding the effectiveness of cancer therapy to be offered as part of
research. In contrast, nurses with greater than 20 years of experience in cancer nursing had the
lowest perception. There was a statistically significant difference in their opinions compared to
nurses’ with 10 years or less experience, but not with nurses who had 11–20 years of
experience. Moreover, there was no statistically significant difference in the opinions of nurses
with 10 or fewer years of experience compared to nurses with 11–20 years of experience.
Nurses who reported that they work in a CI setting had the lowest expectations of the
effectiveness of cancer therapy offered as part of a clinical trial compared to all other nurses.
Furthermore, nurses who reported they work in an inpatient setting on a MSOU had the highest
expectations compared to other nurses. There were statistically significant differences in the
opinion of nurses working on a MSOU compared to HBIC nurses, nurses in a CI setting and to
nurses in indicating “other” work setting on the DIF. Nurses working in BMTU/ICU as well as
MSOU nurses had statistically significant higher expectations, compared to nurses in a CI
setting.
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Nurses with a bachelor’s degree perceived the highest benefit of an experimental
treatment producing a desired effect before being offered to patients compared to the other
nurses in this group. This was in contrast to nurses with a master’s degree or higher who
indicated the lowest perception of benefit of the three groups. The nurses with a master’s
degree or higher had a statistically significant difference in their mean responses, compared to
nurses with a bachelor’s degree or less.
Multiple regression analysis revealed nurse’s education level, work setting, and
whether they worked with clinical trial patients or not were significant predictors of their
perception of patient knowledge and understanding. Compared to nurses who do not work with
clinical trial patients, nurses who work with clinical trial patients perceive that patients
understand their treatment goals, plan and prognosis and that their wishes are respected by
oncologists and nurses. The differences in the PUK subscale scores were statistically
significant. When grouped by work setting, nurses who reported they worked in an outpatient
setting (HBIC and MDO) had higher scores on the PUK compared to the other nurses. Even
though the ANOVA was statistically significant for the group, the post-hoc multiple
comparison test failed to reveal which work settings explained significant differences.
The variable of whether a nurse works with clinical trial patients or not was a
significant predictor for perceptions of informational needs of patients, as measured by the INP
subscale. Nurses who work with, or care for, clinical trial patients had a statistically significant
higher score compared to nurses who do not. This indicates that nurses who do not work with
clinical trial patients perceive that patients are willing to accept side effects, pay more attention
to the benefits of therapy, have their decisions influenced by their families and are afraid to ask
questions. Additionally, statistically significant differences in the INP mean scores were found
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between the nurses by work setting groups. BMTU/ICU nurses perceive, more than the other
four groups, that patients are willing to accept side effects, pay more attention to the benefits of
therapy, have their decisions influenced by their families and are afraid to ask questions. There
were statistically significant differences in their scores on the INP subscale compared to MDO
nurses.
The variables, number of years experience as a cancer RN and whether or not a nurse
works with clinical trial patients, were significant predicators of the RL subscale. Specifically,
differences existed in the perception that nurses have regarding where clinical research should
be conducted, patients’ awareness of their treatments, and the role of oncologists and nurses in
clinical trials. Significant differences were found in the mean scores of nurses who do not work
with, or care for, clinical trial patients compared to nurses who do. This suggests nurses who
do not work with clinical trial patients perceive that clinical research should be conducted only
in cancer centers, oncologists and nurses put too much pressure on patients to participate in
clinical trials, and patients often are unaware that their treatment is part of a research protocol,
compared to nurses who work with clinical trial patients. Finally, nurses with ten or fewer
years of experience, on average, perceived that clinical research should be conducted only in
cancer centers, oncologists and nurses put too much pressure on patients to participate in
clinical trials, and patients are often unaware that their treatment is part of a research protocol,
compared to nurses with 11 years or greater experience in cancer nursing.

CHAPTER V: DISCUSSION AND RECOMMENDATIONS
A. Summary and Discussion of Results
Demographics
The following information regarding the demographic characteristics of the sample is
noteworthy. In terms of gender, this sample was consistent with the membership of ONS, the
majority of ONS members are female and only 3% of its members are male (Brown, 2003;
Kristina Gantner, Personal Communication, July 19, 2006). In this study (N = 301), 98% (n =
295) of the subjects were female and 2% (n = 6) were male. Both the sample and the ONS
membership reflected the general nursing population with the majority over the age of 40
(Buerhaus, 2002). Sixty-six percent of ONS members are over the age of 40 (Kristina Gantner,
Personal Communication, July 19, 2006).
The proportion of master’s prepared nurses in this study is a larger proportion than
reported in the ONS membership (ONS, 2004). Nurses in this study with a master’s degree (in
nursing or any other discipline) as their highest education level, (n = 85) represented 28.2% of
the sample. The proportion of subjects with the diploma and associate’s degree and bachelor’s
degrees in nursing in this study was lower than that of the ONS membership.
The major certification category of subjects was OCN®, with 46.5% of the subjects (n
= 140) reporting that they had this credential. This is comparable to the proportion of OCN®
certified nurses in the ONS membership where 46% report that they have this credential
(Kristina Gantner, personal communication, July 19, 2006).
The largest primary work area reported in the study was the outpatient setting 47.3% (n
= 141), which is similar to the ONS membership, 51% (Kristina Gantner, personal
communication, July 19, 2006). The proportion of nurses working in an in-patient setting was
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38.9% (n = 116), which was also similar to the ONS membership, 39%. Finally, the largest
proportion of subjects reported that their primary position was staff nurse, 38.5% (n = 116).
Proportionally, this is similar to the ONS membership in which staff nurses make up the largest
position (Kristina Gantner, personal communication, July 19, 2006).
Relevance of Research to Prior Literature
Research Question 1. – What are oncology nurses’ attitudes toward the benefits of cancer
clinical trials? The only statistically significant differences found in attitudes toward cancer
clinical trials were between nurses grouped by primary position and work setting. Nurses who
reported they work in a corporate/industry (CI) setting had a more positive attitude compared
to nurses in bone marrow transplant/intensive care unit (BMTU/ICU), in-patient medicalsurgical oncology unit/oncology specialty unit (MSOU) and physician office (MDO). Clinical
trials nurses (CTN) and nurses who reported “other” for primary position on the DIF had more
positive attitudes compared to staff nurses. Additionally, nurses who reported “other” for
primary position had a more positive attitude compared to clinical nurse specialists/nurse
practitioners (CNS/NP).
Burnett et al. (2001) reported in their study that research nurses had statistically
significantly higher mean scores on their attitude subscale, compared to BMTU/ICU nurses,
who had the lowest mean scores on attitudes toward clinical trials. There are several reasons
for the differences found in the measurement of oncology nurses’ attitudes between Burnett et
al. (2001) and this study. First, Burnett et al. (2001) had one demographic question that asked
nurses to indicate their main area of work (i.e., inpatient floor [not ICU/BMTU], ICU or
BMTU, research nurse, etc.). The demographic independent variables in this study were set a
priori and separated work setting and primary position (2 questions on the DIF), which is
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identical to the way the 2006 ONS membership application captures this information.
Therefore, nurses who indicated they work in BMTU/ICU setting were captured under the
primary work setting variable and clinical trial nurses (research nurses) were captured under
primary position variable. It is interesting to note that clinical trial nurses in this study had a
higher mean score (33.6) than BMTU/ICU nurses (30.7) on the ATCR subscale. This result
suggests that clinical trial nurses, in this study, had more positive attitudes toward the benefit
of cancer clinical trials compared to BMTU/ICU nurses. The clinical trial nurses, on average,
agreed more than BMTU/ICU nurses, that clinical research improves standards of care,
patients should participate in research, and would participate in a clinical trial if they had
cancer. However, because they were part of two different independent variables, they were not
tested against one another with ANOVA. Another reason for the differences in nurses’
attitudes in this study compared to results described by Burnett et al. (2001) could be related to
the subscales used to measure attitudes toward clinical trials. Burnett et al. (2001) used six
items from the NAS to make up their subscale. This study used eight items to measure nurses’
attitudes toward clinical trials, the same six items as in Burnett et al. (2001) plus two additional
items that factored together to make up the ATCR subscale.
Research Question 2. – What are nurses’ perceptions about how effective a research
drug or experimental therapy should be before it is offered to patients? Consistent with the
study by Burnett et al. (2001) this study found nurses perceived the benefit of an experimental
therapy should be high prior to being offered to patients. This perceived benefit exceeded the
historical effectiveness of experimental anticancer agents. There have been significant
improvements in treatment for patients with advanced cancer over the past 5 years with
improvements in overall response rates and survival; yet the rates of complete responses have
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been lower than 10% for these palliative treatments (Chu & DeVita, 2005). For earlier stage
cancers the absolute improvements in survival are also small. For example, adjuvant
chemotherapy for breast cancer achieves absolute 10 year reductions in breast cancer mortality
of 5.3% for lymph node positive disease and 12.2% for lymph node negative disease (Early
Breast Cancer Trialists’ Collaborative Group [EBCTCG], 2005). Additionally, in a pooled
analysis of Stage II and III colon cancer patients, overall survival was increased form 64% to
71% with fluorouracil-based chemotherapy, an absolute improvement of 7% (Gill et al., 2004).
Studies evaluating perceptions of the benefits of investigational treatments among
patients with cancer also have demonstrated high expectations regarding clinical cancer
research (Cassileth et al., 1982; Cheng et al., 2000; Daugherty et al., 1995; Meropol et al.,
2003). For example, Meropol et al. (2003) reported that 77% (252 of 338) of patients entering a
Phase I cancer clinical trial estimated their chance of benefit being at least 50%. The
expectations of nurses in this present study parallel these findings.
In this study, nurses with educational degrees other than master’s or doctorate’s had
significantly higher perceptions of the effectiveness a research drug or experimental treatment
should have before being offered to a patient, compared to nurses with master’s degrees or
higher. Additionally, nurses with fewer than 1–10 years experience as a cancer RN had
significantly higher perceptions of benefit compared to nurses with greater than 20 years
experience. Nurses grouped by work setting also demonstrated significant differences in their
perceptions. Nurses working in MSOU had significantly higher perceptions compared to
nurses in HBIC. Nurses in BMTU/ICU and MSOU had significantly higher perceptions
compared to nurses in the corporate or industry setting. Nurses who work in MSOU reported
higher perceptions compared to nurses who reported “other” for work setting on the DIF.
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Finally, staff nurses had significantly higher expectations compared to CNS/NP and nurses
who reported “other” for primary position on the DIF.
Why nurses with fewer than 1–10 years experience as a cancer RN had significantly
higher perceptions of benefit compared to nurses with greater than 20 years experience is
unclear. One explanation may be that the longer an oncology nurse is in practice, the more
experience they may have with clinical trials, and, as a result, they have seen experimental
therapies produce benefits in the single digits. The investigator was unable to identify other
research addressing this issue.
Burnett et al. (2001) reported that research nurses believed a new therapy should have a
25% (median) chance of benefit before entering a clinical trial. For BMTU/ICU nurses,
outpatient and inpatient nurses, and operating room nurses, the response median was 50%. The
use of reporting the median response in the study by Burnett et al. (2001) makes it difficult to
compare to the present study which reported mean response. Mean responses were used
because ANOVA tests for significant differences in mean scores between groups as opposed to
a median score.
Research Question 3. – What are oncology nurses’ perceptions regarding patients’
understanding of clinical trials and the treatment regimen? Statistically significant differences
were found in the mean scores on the PUK subscale in nurses who worked with clinical trial
patients compared to those who did not. The only other group that demonstrated significant
differences in their perceptions of patient understanding and knowledge of the treatment
regimen was the variable of work setting. Surprisingly, the post hoc test for multiple
comparisons failed to demonstrate which of the work settings (nurses who reported being
employed in these work settings) had significant differences in their PUK scores. However,
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nurses in MDO had the highest mean score compared to all other nurses in this group. This
indicates that these nurses had greater agreement with items relating to patients understanding
their treatment goals, plan and prognosis, and their wishes being respected by oncologists and
nurses compared to other nurses. These findings may reflect MDO nurses’ involvement with
patient education. In many oncology physicians’ offices, the nurse provides additional
education related to the treatment goals. Perhaps MDO nurses had more extensive experience
observing physicians providing patients with information.
Daugherty et al. (1995) conducted a pilot survey study of 30 cancer patients who had
given informed consent to participate in a Phase I clinical trial. Concurrently, the oncologists
identified by the surveyed patients as responsible for their care were surveyed as well.
According to Daugherty et al. (1995) cancer patients who participate in Phase I clinical trials
appear to have an adequate self perceived knowledge of the risks of experimental therapy;
however, only a minority has an adequate understanding of the purpose of these trials.
Research Question 4. – What factors do nurses perceive influence a patients’ decision
to participate in a cancer clinical trial? Nurses’ perceptions of patient expectations and reports
of patient expectations of the outcomes of a cancer clinical trial are consistent. There was
agreement between this study and other studies (Daugherty et al., 1995; Yoder et al., 1997;
Meropol et al., 2003) on several factors that nurses believed influenced patient participation in
clinical trials. Ninety-three percent of nurses in this study reported that patients entered a
clinical trial with a belief of a cure for their cancer. According to published literature, which
examined patients’ perceptions and motivations to participate in Phase I cancer clinical trials,
most patients with cancer reported that their decision to participate in a Phase I clinical trial
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was based on the hope of therapeutic benefits (Daugherty et al., 1995; Schuta & Burnett, 2000;
Yoder et al., 1997).
Daugherty et al. (1995) conducted a pilot survey study of 30 cancer patients who had
given informed consent to participate in a Phase I clinical trial. Concurrently, 18 oncologists
identified by the surveyed patients as responsible for their care were surveyed as well.
Daugherty et al. (1995) reported that 85% of patients decided to participate in a Phase I clinical
trial for reasons of a possible therapeutic benefit.
Consistent with this finding, Yoder et al. (1997) described the expectations and
experiences of patients entering Phase I clinical studies. A convenience sample of 37 patients
who already had agreed to participate in a Phase I clinical trial were interviewed using
structured entry and exit questionnaires. Yoder et al. (1997) reported at the time patients
entered a clinical trial, 85% expected a decrease in tumor size. Although these studies did not
specifically address the issue of “cure,” an expectation of tumor shrinkage and expectation of
cure were viewed by patients as an expectation of therapeutic benefit from a clinical trial.
Schuta and Burnett (2000) explored the factors that influenced a patient’s decision to
participate in a Phase I cancer clinical trial. Two focus groups were conducted with six patients
participating in the first and two patients in the second focus group (total N = 8). The authors
reported that participants in their study expressed hope for a cure and trusting the oncologist’s
advice as the primary factors for participating in a Phase I clinical trial. The majority (87.5%, n
= 7) expressed surprise that anyone would participate in an experimental study for altruistic
reasons. Moreover, Meropol et al. (2003) described and compared the perceptions of cancer
patients and their physicians regarding Phase I clinical trials. Eligible patients had been offered
participation in a Phase I trial but had not yet begun treatment. Each patient’s physician also
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served as a study subject. Forty eight physicians and 128 patients completed surveys with
domains including perceptions of potential benefit and harm from treatment (experimental and
standard), relative value of quality and length of life, and perceived content of patientphysician consultations. Meropol et al. (2003) reported that 39% of patients entering a Phase I
trial believed they would be totally cured; 26% believed their cancer would be reduced, and
30% believed it would be controlled.
Research Question 5. – What are nurses’ perceptions of patients’ decision-making
processes and the desire for information regarding clinical trial participation? The nurses’
perceptions of patients’ perceptions of the treatment and research process and influences in
patient’s decisions were measured by the INP subscale. The INP subscale was reverse coded;
therefore a lower score indicated more agreement with the items on the subscale. This
translates to a lower score indicating more agreement with statements that patients are
frightened to ask questions, patients decisions regarding therapy is strongly influenced by their
family preferences, and patients are willing to accept side effects for a small benefit in therapy.
Two groups emerged as having significant differences in their perceptions, whether nurses
work with clinical trial patients (or not), and work setting. Nurses who reported they did not
work with clinical trial patients had a significantly lower mean score than nurses who did, and
BMTU/ICU nurses had a significantly lower mean score compared to MDO nurses but not to
nurses in any other work setting. This indicates that BMTU/ICU nurses agreed more with
statements that patients are frightened to ask questions, patients decisions regarding therapy is
strongly influenced by their family preferences, and patients are willing to accept side effects
for a small benefit in therapy. This may be inherently related to the type of nurse-patient
relationship in the BMTU/ICU setting. Patients usually are more gravely ill, and may, be
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incapable or less interested in having treatment related knowledge (Ende, Kazis, Ash, &
Moskowitz, 1989; Leydon et al., 2000).
Research Question 6. – What are the perceptions of nurses regarding where clinical
research should be conducted and the role of oncologists and nurses in clinical trials? The RL
subscale evaluated nurses’ perceptions of the role oncologists and nurses in clinical research,
awareness of patients and location of clinical trials. The RL subscale was reverse coded;
therefore a lower score indicated more agreement with items such as oncologists and nurses
put too much pressure on patients to participate in research, patients are unaware that their
treatment is part of a research protocol and clinical research should only be conducted in
cancer centers. Two groups emerged having significant differences in their mean RL scores,
nurses working with clinical trial patients (or not) and years of experience as a cancer RN.
Nurses who did not work with clinical trial patients had lower mean scores on the RL subscale
compared to nurses who do and nurses with less than 1–10 years experience as a cancer RN
had significantly lower scores compared to nurses with more experience. The reason why
nurses with less than 1–10 years experience and nurses who did not work with clinical trial
patients had more agreement with items such as, oncologists and nurses put too much pressure
on patients to participate in research, patients are unaware that their treatment is part of a
research protocol and clinical research should only be conducted in cancer centers may be
explained by the fact that these groups may have less experience with clinical trials and have
not experienced patient-oncologist interaction regarding participation in clinical trials.
Research Question 7. Five stepwise multiple regression models were constructed to
determine if the independent variables (age, education level, number of years as a cancer RN,
whether nurses care for clinical trial patients [or not], work setting, and primary position) serve
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as significant predictors related to attitudes and perceptions as measured by the four subscales
(ATCR, PUK, INP and RL) and Item 15 on the modified NAS. The variables of primary
position, years a cancer RN, work setting, educational level, and whether or not a nurse works
with clinical trial patients were significant predictors of attitudes toward cancer clinical trials,
perceptions of patients’ knowledge of clinical trials, treatment plans, need for information, and
perceived benefit about how effective a research drug or experimental therapy should be shown
to be before it is offered to patients. However, caution is needed in interpreting the data, as it is
difficult to make definitive statements that the predictors identified in this regression analysis
serve as great predictors of attitudes and perceptions, since all of the regression models
accounted for so little variance. The R² values for the five regression models ranged from 0.025
to 0.144, indicating the models accounted for 2.5% to 14.4% of the variance in attitude and
perception scores. This indicates there are other variables that predict attitudes and perceptions
better than the independent variables chosen for this study, and these variables are unknown.
Burnett et al. (2001) found that practice setting and older age predicted nurses’
positive attitudes and perceptions toward clinical trials. However, they also had low R² values
for their subscales (10%). Older age as a predictor of positive attitudes and perceptions is in
contrast to the findings of this study; age was not found to be a predictor for attitudes and
perceptions from the multiple regression models constructed for this study. The reason for this
difference is unclear and the investigator was unable to identify any other research addressing
this issue.
Additional information. The oncology nurses in this study were supportive of the
importance of cancer clinical trials improving standards of care in oncology, but not
necessarily willing to participate as research subjects if they had cancer. This finding is
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consistent with the findings by Burnett et al. (2001) but not to the same magnitude. In both
studies greater than 95% of nurses agreed that clinical research improves standards of care in
oncology. Burnett et al. (2001) found 56% of nurses agreed that patients should be encouraged
to participate in research, while only 35% of nurses stated that they would prefer treatment in a
clinical trial. This study found 75% of nurses agreed that patients should be encouraged to
participate in research while 51% of nurses stated that they would prefer treatment in a clinical
trial. More nurses in this study agreed that patients should be encouraged to participate in
research compared to Burnett et al. (2001), 75% vs. 56%. Furthermore, more nurses in this
study were willing to participate in a cancer clinical trial if they had cancer compared to
Burnett et al. (2001), 51% vs. 35%. These differences may be due to the timing of the data
collection; Burnett et al. (2001) collected their data more than 5 years before data collection for
this study. Within that time, the NCI has developed and advertised a Clinical Trials Education
Series (NCI, 2006) and the ONS has updated its position statement on Cancer Research and
Cancer Clinical Trials three times. A paragraph contained in the position statement relative to
this study states: “Barriers to access and environment include system barriers, healthcare
barriers, and patient barriers. Modifying attitudes, changing perceptions, and increasing
awareness about clinical trials among these groups are paramount to overcoming many of the
present barriers” (ONS position statement, 2004, p. 2).
Because of these initiatives, nurses may have a greater awareness of the importance of
cancer clinical trial participation. Also, this study collected data from oncology nurses who
practice in varied work settings compared to Burnett et al. (2001), they collected data from
nurses who only worked in a comprehensive cancer center and this may also be a reason for the
differences in how many nurses agree that patients should be encouraged to participate in

127
research and how many nurses themselves would participate in a clinical trial if they had
cancer. Cassileth et al. (1982) found that willingness to participate in research varies
depending on whether a subject considers the question of participation as referring to
hypothetical individuals rather than themselves.
There were striking differences between the nurses’ perceptions of the influence of
nurses and oncologists on patients’ decisions to enter clinical trials between this study and the
only other study to report on oncology nurses attitudes toward cancer clinical trials (Burnett et
al., 2001). Almost all the nurses in both studies agreed that nurses respected patient wishes.
However, Burnett et al. (2001) reported that 62% of nurses thought that physicians respected
patients’ wishes, whereas in this study approximately 83% of nurses agreed with this. Also,
more than 25% of nurses in the Burnett et al. (2001) study agreed that doctors put too much
pressure on patients to participate in clinical trials. In this study less than 10% of nurses agreed
with this statement. More than 80% of the nurses in this study perceived that patients were
actually well informed when they chose to participate in a clinical trial. This is higher than
what has been reported by Burnett et al. (2001) who reported that only 56% of nurses thought
that patients were well informed when they chose to participate in a clinical trial. Additionally,
Burnett et al. (2001) reported that less than 50% of the nurses they surveyed agreed with the
statement “patients understand their prognosis and goals of therapy” (p.1190) whereas, this
study found 68% of the nurses agreeing with this statement. Finally, almost one quarter of the
nurses surveyed by Burnett et al. (2001) agreed that patients are often unaware that their
treatment is part of a research protocol, and approximately 10% of nurses in this study agreed
with this statement.
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The investigator acknowledges that the responses by the nurses surveyed by Burnett et
al. (2001) and the nurses in this study cannot be directly compared. Burnett et al. (2001)
surveyed the nurses employed at one comprehensive cancer center. This study surveyed a
random sample of oncology nurses who are members of ONS living in the U.S. Also, Burnett
et al. (2001) published their data 5 years before this study, as such, attitudes can change over
time. Additionally, the NAS had been used in only one prior pilot study (Burnett et al., 2001)
and was modified with permission from the authors (see Appendix D). This modification of a
relatively new and infrequently used instrument may also explain the low reliability of the INP
and RL subscales.
Study Results and Theoretical Framework
The theoretical framework on which this study was based was the Theory of Reasoned
Action (TRA) by Ajzen and Fishbein (1980). This study was descriptive and exploratory and
was not designed to fully test the TRA. According to the theory, in general, an individual will
hold a favorable attitude toward a given behavior if he/she believes that the performance of the
behavior leads to mostly positive outcomes. Conversely, if the individual believes that mostly a
negative outcome will result from the behavior, he/she will hold a negative attitude toward it.
Concepts of the theory define the nurse’s own beliefs, as well as, the perceived beliefs
of those groups that are in a position to influence the ideas and actions of the nurse. These
beliefs and actions pertain to the nurse’s relationship with the patient contemplating enrollment
or already enrolled in a cancer clinical trial. Therefore, the combination of the nurse’s beliefs
and the group belief could lead one to action depending upon which set of beliefs are valued
more (or is perceived to lead to a positive outcome) by the nurse, thus forming an attitude on
the part of the nurse. Behavior, in turn, is deemed a function of intention.
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Therefore, factors associated with intention need to be evaluated to understand and
predict behavior (Levin, 1999). One way to evaluate intention is to assess attitudes and
perceptions, and this study was an exploration of oncology nurses attitudes and perceptions
toward cancer clinical trials. Attitudes need to be evaluated before predictions can be made as
to how an individual may behave. One behavior that nurses may perform is to provide
education to patients and to clarify information that a patient may not understand. This fact is
underscored by the study by Aaronson et al. (1996). The authors evaluated a strategy of
providing additional information to patients considering entry into Phase II or III trials at the
Netherlands Cancer Institute (N = 180). Patients were randomized to the standard consent
interview, or the standard interview followed by a telephone call several days later from a
clinical trials nurse to further discuss the information provided in the consent interview. This
nursing intervention was shown to have a positive effect on cancer patients’ awareness of the
most important issues surrounding clinical trials in which they are asked to participate.
Overall, oncology nurses in this study had positive attitudes toward cancer clinical
trials. Moreover, 98% of nurses in this study agreed that clinical research was important in
improving future standards of care. It is impossible to make direct correlations that the
oncology nurses surveyed in this study will perform positive behaviors because, in general,
they have positive attitudes toward cancer clinical trials. Further research is needed to construct
a model or study design that will measure attitudes, the perceived beliefs of significant others,
and intentions, and correlate them with a behavior, such as, educational information given by
oncology nurses to clinical trial patients.
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B. Additional Limitations
After all the data from this study were analyzed there were several additional
limitations that became clear.
1. This study used a mailed survey design to collect data from a national sample of
oncology nurses. Three hundred and one surveys were used in the analysis equating to 30% of
the population sampled. Despite using a stratified random sample design to attempt to obtain a
representative sample of oncology nurses who were ONS members, the results may not be
representative of entire approximate 32,000 members of ONS. Thus, an inherent limitation
with mailed surveys is nonresponse bias (Dillman, 2000). As such, nonresponse bias could
have reduced the random probability sample of this study to essentially a convenience sample
and consequently, the conclusions become much weaker. It is unknown if nonresponders
would have answered the items on the NAS differently from responders.
2. The population studied was a defined group of oncology nurses who are ONS
members who allowed their names and addresses to be made public. Their attitudes and
perceptions may not necessarily parallel those of nononcology nurses, oncology nurses not
members of ONS, or ONS members who did not allow their contact information to be made
public. Additionally, geographic diversity is unknown from this population of nurses, and there
may have been differences in patterns of care of cancer patients based on where they live
(Gregorio et al., 2001; Hanlan et al., 1995). There are standards of care that have been defined
by cancer research leaders; however, there remains a “gap” between the recommended
standards and oncology care delivered by community oncologists (Love, 2005). Therefore,
nurses from one part of the country may approach cancer clinical trials differently than nurses
in another part of the country. Geographic information was not captured on the DIF.
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3. The modified NAS may have been a limitation in the conclusion drawn from the data
analysis. This is based upon the low coefficient of determination (R²) found in this study and
its ability to define variables (groups of nurses) that predict positive attitudes toward clinical
trials. There may be other variables that were not captured on the DIF that serve as better
predictors of attitudes and perceptions, such as geographic location of employment. Along the
same line, the DIF questions for work setting and primary position are identical to the ONS
membership application, and there was no way to differentiate between nurses working in a
comprehensive cancer center and nurses in other settings. In retrospect, the investigator could
have included a yes/no question on the DIF that asked “Do you work in a comprehensive
cancer center?”
4. The original NAS used two subscales to measure attitudes and perceptions and was
designed to measure two constructs (attitudes and perceptions) and used one 6-item subscale to
measure attitudes and another 6- item subscale to measure perceptions. In retrospect, it may
have been more appropriate to perform a factor analysis to evaluate two subscales. This is
supported by the fact that the INP and RL subscales, determined by the factor analysis had low
Cronbach’s alpha.
5. The TRA attempts to predict human behavior, based on concepts of personal beliefs,
which lead to attitudes toward the behavior, and perceived beliefs of others, which lead to
subjective norms. The attitudes and subjective norms lead to behavioral intention and then
finally to performing a behavior. This study was based on one side of the TRA and addressed
nurses’ attitudes only. It did not take into account the nurses perceived beliefs of others and
subjective norms
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6. Finally, the inclusion of nurses from the corporate/industry setting may have
confounded the generalizability of the results, because it is hypothesized that this group works
in the research field and may have very strong positive attitudes toward clinical trials.
C. Implications
Oncology nurses play a key role in the clinical and research settings by serving as direct
caregivers, patient advocates, educators, counselors, as well as facilitators of clinical trials. As
such, nurses have a major role in cancer clinical trials, yet not much research into their
attitudes and perceptions has been undertaken. Nurses’ attitudes and perceptions regarding
cancer clinical trials may ultimately dictate their behaviors towards patients enrolled in or
contemplating enrollment in such trials. By investigating oncology nurses attitudes and
perceptions toward cancer clinical trials this study may begin to assess the behavior of
oncology nurses towards clinical trial patients. These behaviors can include direct patient care,
coordination of care, patent education, and patient advocacy. The findings of this study have
implications for nursing education, nursing practice, and the conduct of clinical trials. For
example: In-patient nurses (BMTU/ICU & MSOU) compared to MDO & HBIC were less
likely to agree that patient understood their management plan, understood their prognosis and
therapy goals, and patients are well informed when they choose to participate in a clinical trial.
Patient care and the conduct of clinical trials may be improved if these concerns are reconciled.
D. Recommendations for Further Research
Based on the results obtained from this study the investigator recommends the
following areas that need to have further exploration.
The entire modified NAS had high internal consistency, with a Cronbach’s alpha of
0.72; however, the Cronbach’s alpha of RL and INP subscales were 0.47 and 0.56,
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respectively, indicating that the subscales had fair to poor reliability. Because of this, further
research is needed to develop an improved instrument to measure oncology nurses’ attitudes
and perceptions of the informational needs of patients involved in clinical trials. One option is
to conduct a qualitative study using focus groups for the purpose of exploring common themes
related to nurses’ attitudes and perceptions toward cancer clinical trials. It might be
advantageous to use focus groups to collect these data using nurses from the ONS clinical trial
nurses special interest group (SIG) and from the pharmaceutical/industry nursing (PIN) SIG.
The reason for inclusion of this later group is this study revealed that nurses in the CI setting
and CTN had more positive attitudes toward cancer clinical trials and more realistic
expectations of the benefit of cancer therapy offered as research. Nurses who are members of
the clinical trials SIG and PIN SIG most likely represent CI nurses from this study. From this
qualitative study there may be items that are common to themes found on the modified NAS;
these items could then be incorporated into the NAS. The NAS could continue to be modified
and pilot tested for measuring nurses’ attitudes and perceptions.
Once an instrument measuring nurses’ attitudes and perceptions has been refined, a
further recommendation would be to construct a model that will measure attitudes, the
perceived beliefs of significant others, and intentions, then correlate them with a behavior, such
as, educational information given by oncology nurses to clinical trial patients, to formally test
the Theory of Reasoned Action. Finally, an intervention study could be undertaken looking at
providing educational strategies that may change the attitudes and behaviors of oncology
nurses working with clinical trial patients. This may help with increasing the number of
patients into clinical trials.
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E. Conclusion
This study was only the second and largest study to date exploring oncology nurses’
attitudes toward clinical trials and their perceptions of patient understanding and knowledge.
This is underscored by the fact that a systematic review of the relevant literature from 1996 to
2006, relating to the barriers, modifiers and benefits involved in participating in randomized
controlled trials of cancer therapies as perceived by healthcare providers and patients, was
undertaken by the Center for Reviews and Dissemination (CRD), University of York (Fayter,
McDaid, Ritchie, Stirk, & Eastwood, 2006). In their review, the authors found 17 studies
examining attitudes of health professionals to participation in cancer clinical trials. However,
there was only one study which explored the views of oncology nurses, and that study was by
Burnett, et al. (2001).
Despite high internal consistency of the entire modified NAS, the four subscales
derived from the factor analysis revealed varying degrees of internal consistency. This study
discovered significant predictors to attitudes and perceptions; however, all R² (coefficient of
determination) values were very low, indicating that there were some other unknown variables
that could be better predictors than the ones used in this study. On average, oncology nurses
had positive attitudes towards cancer clinical trials. However, statistically significant
differences were found between nurses grouped by primary work setting and primary position.
Additionally, as a whole, these nurses perceived that patients have enough information to make
decisions regarding clinical trial participation and they somewhat disagreed that clinical
research should be conducted only in cancer centers, oncologists and nurses put too much
pressure on patients to participate in clinical trials, and patients are often unaware that their
treatment is part of a research protocol. Significant differences in these perceptions were found
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between the following variables: primary work setting, number of years in cancer nursing, and
whether or not a nurse works with clinical trial patients. Consistent with prior research,
oncology nurses perceived that experimental cancer treatments should have a large benefit
before being offered to patients. Moreover, there were statistically significant differences in
this perceived benefit between the nurses grouped by number of years in cancer nursing,
primary work setting and highest education level. More research is needed to explore the
reasons for these differences in attitudes and perceptions. Finally, more research is needed to
truly evaluate the TRA as a model of educational behaviors nurses use providing education to
patients involved with cancer clinical trials.
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Survey of Nurses Attitudes Toward Cancer Clinical Trials v.4
Modified with permission (Burnett et al. 2001).
I.

Clinical research using patients as research subjects.
For the following statements please mark the category closest to your opinion.
Strongly Somewhat
disagree disagree

Neutral

Somewhat
agree

Strongly
agree

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1. Conducting patient research is an
important role of oncologists.
2. Clinical research should be conducted
only in cancer centers/institutes.
3. It is appropriate for oncologists to invite
their clinic patients to be subjects in trials
that they conduct.
4. It is appropriate for oncologists to be the
person consenting research subjects for
their trials, if the research
subjects are their own clinic patients.
5. Clinical research improves patient
care for the patient involved.
6. Hospitals that conduct clinical
research have better standards of care
than hospitals that do not.
7. Clinical research in oncology is
important in improving future standards of
care in oncology.
8. Patients should be encouraged to
participate in research.
9. Oncologists put too much pressure on
patients to participate in clinical trials.
10. Nurses put too much pressure on
patients to participate in clinical trials.
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Strongly Somewhat
disagree disagree

Neutral

Somewhat
agree

Strongly
agree

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1
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3

4
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1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

11. If I had cancer, I would prefer to be
treated as part of a clinical trial.
12. In general, patients are well informed
when they choose to participate in a
clinical trial.
13. Patients are often unaware that their
treatment is part of a research protocol.
14. Patients participate in research
because of:
A. wish for cure

B.

wish for improved quality
of life (i.e., symptom
control)

C.

hope for better medical
care

D.

desire to please their
oncologist

E.

pressure from oncologist

F.

wish to help others

G.

family wishes

H.

no other option

I.

inability to accept that
nothing else can be done

J.

inability to accept death
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15. In your opinion, in order for a research drug or experimental therapy to be offered to
patients, it should have at least ___________% chance of producing a desired effect (please
insert a number)
II.

Patient care and communication
For the following statements please mark the category closest to your opinion.
Strongly
disagree

Somewhat
disagree

1

2

1

Neutral

Somewhat
agree

Strongly
agree

3

4

5

2

3

4

5

1

2

3

4

5

1

2

3

4

5

3

4

5

16. Patients’ wishes regarding treatment are
respected by nurses.
17. Patients’ wishes regarding treatment are
respected by oncologists.
18. Patients understand their plan of
care/treatment.
19. Patients understand their prognoses and
therapy goals.
1

2

20. Patients’ prognoses are usually well
explained.
1

2

3

4

5

1

2

3

4

5

21. Patients want to be informed.

22. When being told about their therapy,
most patients pay more attention to
potential benefits of therapy
than side effects.
1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

23. Most Patients are willing to accept side
effects for even a small benefit of therapy.
24. Patients are often frightened to ask
questions.
25. Patients’ decisions whether to
accept or not accept toxic chemotherapy is
strongly influenced
by their family preferences.
26. Oncologists believe that patients are
willing to accept side effects for even a
small benefit of therapy.
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Demographic Information Form
The following information is requested so that the investigator may gain a better
understanding of demographic characteristics related to the nurse-patient. Please answer
all questions by checking the appropriate box or filling in the blank

1. What is your age? __________ years old (please insert a number)

2. Your gender:

Female

Male

3. Indicate your highest level of nursing education.
Check
Level

Educational
Level
Diploma in nursing
Associate degree in nursing
Associate degree in another field
Baccalaureate degree in nursing
Baccalaureate degree another field
Master’s degree in nursing
Master’s degree in another field
Doctoral degree in nursing
Doctoral degree in another field

4. Do you work with or care for patients contemplating enrollment in or currently
enrolled in cancer clinical trials?
Yes
No
5. What certifications do you have in oncology nursing? (Check all that apply, if none go
to question #6).
Certification Type
Oncology Certified Nurse
(OCN)
Advanced Oncology Nurse
Practitioner (AOCNP )

Yes

Advanced Oncology
Certified Nurse (AOCN)

Yes

Yes

Advanced Oncology Clinical
Nurse Specialist (AOCNS)

Yes

Other__________________(please specify)
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6. Number of years an RN
Please indicate your total number of years of experience as a RN where you had direct
patient contact at least 8 hours per week. (Round to the nearest whole
year)._______________years (please insert a number).
7. Number of years an RN in Cancer Care
Please indicate your total number of years of experience as a RN in CANCER care where
you had direct patient contact at least 8 hours per week.
(Round to the nearest whole year)._______________years (please insert a number)
8. Percentage of patients offered cancer clinical trials
At your place of employment/practice setting, what percentage of patients are offered any
type of cancer clinical trials? (eg. NCI sponsored, industry sponsored, investigator
initiated studies).____________________ % (please insert a number)

9. What is your primary work setting? (Select one)
In-patient
Bone Marrow Transplant Unit
Intensive Care Unit
Medical/Surgical Unit- General
Medical/Surgical Unit-Oncology
Oncology Specialty Unit
Other__________________________________ (please specify)
Outpatient
Home Care
Hospice
Hospital Based Clinic/Infusion Center
Physician Office
Radiation-Free Standing
Radiation-Hospital Based
Other__________________________________ (please specify)
Other
Corporate/Industry
Extended Care Facility
HMO/Managed Care
School of Nursing
Self Employed
Other__________________________________ (please specify)

10. What is your primary position? (Select one)
Staff Nurse
Clinical Nurse Specialist
Nurse Practitioner
Nurse Educator
Clinical Trials Nurse
Nurse Researcher
Nurse Manager
Academic Educator
Case Manager
Other____________________________________ (please specify)
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Paul D’Amico
From:
Sent:
To:
Subject:

Meropol, M.D., Neal [NJ_Meropol@fccc.edu]
Monday, September 20, 2005 9:52 AM
‘Paul D’Amico’
RE: Dissertation

Paul,
Thank you for the follow up again, and good luck with your thesis.
Feel free to modify the instrument as you propose. I’ll be most
interested in your results.
This e-mail should be sufficient for you to proceed comfortably.
Neal J. Meropol, M.D.
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia PA 19111
phone: (215)728-2450
fax: (215)728-3639
-----Original Message----From: Paul D’Amico [mailto:damicop@duq.edu]
Sent: Monday, September 20, 2005 9:31 AM
To: nj_meropol@fccc.edu
Subject: Dissertation
Dear Dr. Meropol,
I hope you are well. Once again I want to bring you up to date with my
doctoral
dissertation.
As I previously informed you, I want to use your Nurses’ Attitude
Survey in my data collection and want to modify it by removing the
section on “Nurses’ Role in a Comprehensive Cancer Center” since this
is beyond the scope of my study.
Additionally, I want to remove the areas for written comments (have the
subjects only answer the Likert scale items) and I want to capture the
demographic information on a separate form and remove it from the
Nurses’ Attitude Survey.
If you think we can modify the tool as outlined above, then I will need
a signed letter from you, giving me permission to use your tool in a
modified form for my dissertation.
Thank you for reading this e-mail,
Sincerely,
Paul D’Amico
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School of Nursing

Graduate Programs
5th Floor Fisher Hall
Telephone: 412.396.6550

DUQUESNE UNIVERSITY
600 FORBES AVENUE

♦ PITTSBURGH, PA 15282

Dear Oncology Nurse,
Three weeks ago a survey packet was mailed to you. I am conducting research for my doctoral
dissertation and I am seeking your attitudes toward cancer clinical trials and your perceptions of patient
understanding. Your participation in this study is voluntary.
You were randomly selected to participate in this survey from ONS members who indicated that their
primary functional area was patient care or research with adult patients and any primary position other
than researcher/principal investigator. If you do not meet these criteria please place a check mark in this
box
and mail this letter back to me in the enclosed stamped addressed envelope. If you do meet
these criteria please complete the study forms as outlined below
If you have completed and returned your survey to me, please accept my sincere thanks. If
not, please do so today. I am grateful for your help because your attitudes and
perceptions regarding clinical trials are important to oncology nursing and to help us
understand this aspect of cancer care.
If you have misplaced the survey another one is included with a stamped, addressed return envelope.
There are two forms for you to complete.
•
The Nurses’ Attitudes Survey (modified) contains statements regarding your attitude towards
benefit of clinical trials, your perceptions of patient understanding, and your perceptions about patients’
reasons for participating as research subjects.
•
Demographic Information Form which asks for information such as age, education level,
functional role, practice setting etc.
It should take you less than 10 minutes to complete the forms.
When you are finished, place all the materials in the stamped, addressed envelope provided and mail it to
me. Your response will be your implied consent. If you have any questions, please at 631-987-4695 or
my dissertation chair Dr. Gladys Husted at 412-396-6544. If you have any further questions about your
rights regarding this study you may call Dr. Paul Richer, Chair of the Duquesne University Institutional
Review Board (IRB) at 412-396-6326.
.
In advance, thank you for helping to describe this aspect of cancer nursing practice.
Sincerely,

Paul G. D’Amico, RN, MS, OCN, PhD(c)
Doctoral Student Duquesne University School of Nursing
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